Transplantation of Schwann Cells and Olfactory Ensheathing Glia after Spinal Cord Injury : Does Pretreatment with Methylprednisolone and Interleukin-10 Enhance Recovery ?	1
Transplantation of Schwann Cells and Olfactory Ensheathing Glia after Spinal Cord Injury	1
Transplantation of Schwann Cells	1
Transplantation	1
Schwann Cells	20
Olfactory Ensheathing Glia after Spinal Cord Injury	38
Olfactory Ensheathing Glia	38
Spinal Cord Injury	71
Does Pretreatment with Methylprednisolone and Interleukin-10 Enhance Recovery	91
Does Pretreatment	91
Methylprednisolone and Interleukin-10	114
Recovery	160
DAMIEN DANIEL PEARSE , ALEXANDER EDUARDO MARCILLO , MARTIN OUDEGA ,2 MICHAEL PAUL LYNCH , PATRICK MCGHEE WOOD ,2 and MARY BARTLETT BUNGE1 ,2 ABSTRACT Methylprednisolone -LRB- MP -RRB- and interleukin-10 -LRB- IL-10 -RRB-	171
DAMIEN DANIEL PEARSE	171
ALEXANDER EDUARDO MARCILLO , MARTIN OUDEGA ,2 MICHAEL PAUL LYNCH , PATRICK MCGHEE WOOD ,2 and MARY BARTLETT	193
ALEXANDER EDUARDO MARCILLO , MARTIN OUDEGA ,2	193
MICHAEL PAUL LYNCH , PATRICK MCGHEE WOOD ,2 and MARY BARTLETT	237
MICHAEL PAUL LYNCH	237
PATRICK MCGHEE WOOD ,2	257
MARY BARTLETT	283
BUNGE1 ,2	297
ABSTRACT Methylprednisolone -LRB- MP -RRB- and interleukin-10 -LRB- IL-10 -RRB-	307
ABSTRACT Methylprednisolone -LRB- MP -RRB-	307
ABSTRACT Methylprednisolone	307
MP	336
interleukin-10 -LRB- IL-10 -RRB-	344
interleukin-10	344
IL-10	360
tissue protective	371
spinal cord injury -LRB- SCI -RRB-	403
spinal cord injury	403
SCI	423
their combination	429
additive protection -LRB- Takami et al. , 2002a -RRB-	454
additive protection	454
Takami	475
et al. , 2002a	482
et al.	482
2002a	490
Our study examined if acute administration of MP -LRB- 30 mg/kg i.v. at 5 min , and 2 and 4 h after injury -RRB- and IL-10 -LRB- 30mg/kg i.p. at 30 min after injury -RRB- increases the efficacy of Schwann cell -LRB- SC -RRB- or SC plus olfactory ensheathing glia -LRB- SC/OEG -RRB- grafts	498
Our study	498
acute administration of MP -LRB- 30 mg/kg i.v. at 5 min , and 2 and 4 h after injury -RRB- and IL-10 -LRB- 30mg/kg i.p. at 30 min after injury -RRB-	520
acute administration	520
MP -LRB- 30 mg/kg i.v. at 5 min , and 2 and 4 h after injury -RRB- and IL-10 -LRB- 30mg/kg i.p. at 30 min after injury -RRB-	544
MP	544
30 mg/kg i.v. at 5 min , and 2 and 4 h after injury	548
30 mg/kg i.v.	548
5 min	565
2 and 4 h after injury	576
2 and 4 h	576
injury	592
IL-10	604
30mg/kg i.p. at 30 min after injury	611
30mg/kg i.p. at 30 min	611
30	627
injury	640
the efficacy of Schwann cell -LRB- SC -RRB- or SC plus olfactory ensheathing glia -LRB- SC/OEG -RRB- grafts	658
the efficacy of Schwann cell -LRB- SC -RRB-	658
the efficacy	658
Schwann cell -LRB- SC -RRB-	674
Schwann cell	674
SC	688
SC plus olfactory ensheathing glia -LRB- SC/OEG -RRB- grafts	695
SC	695
olfactory ensheathing glia -LRB- SC/OEG -RRB- grafts	703
rat thoracic cord 1 week	764
rat thoracic cord	764
1 week	782
contusive injury	795
Efficacy	813
histology , anterograde and retrograde tracing , immunohistochemistry for gliosis and specific nerve fibers , and several behavioral tests	840
histology , anterograde and retrograde tracing	840
histology	840
anterograde	851
retrograde tracing	867
retrograde	867
immunohistochemistry for gliosis and specific nerve fibers	887
immunohistochemistry	887
gliosis and specific nerve fibers	912
several behavioral tests	951
Administration of MP/IL - 10 or SC or SC/OEG transplantation	977
Administration	977
MP/IL - 10 or SC or SC/OEG transplantation	995
MP/IL	995
10 or SC or SC/OEG transplantation	1002
10	1002
SC or SC/OEG transplantation	1008
the total volume of a 9-mm segment of cord	1061
the total volume	1061
a 9-mm segment of cord	1081
a 9-mm segment	1081
cord	1099
the injury site	1117
12 weeks	1136
The combination of either SC or SC/OEG transplantation with MP/IL -10	1146
The combination	1146
either SC or SC/OEG transplantation	1165
SC	1172
SC/OEG transplantation	1178
MP/IL -10	1206
cavitation	1242
The individual treatments	1254
the volume of normal-appearing tissue	1308
the volume	1308
normal-appearing tissue	1322
injury-only controls	1358
significant decreases in the volume of normal-appearing tissue	1389
significant decreases	1389
the volume of normal-appearing tissue	1414
the volume	1414
normal-appearing tissue	1428
MP/IL -10 and cell grafts	1467
MP/IL -10	1467
cell grafts	1480
MP/IL -10	1518
SC/OEG grafts	1534
serotonergic fiber growth	1576
the graft	1607
more reticulospinal fibers caudal to the graft	1628
more reticulospinal fibers	1628
the graft	1665
combination with MP/IL -10	1676
combination	1676
MP/IL -10	1693
further increase fiber number	1710
Only the combination of MP/IL - 10 with SC/OEG transplants	1741
Only the combination	1741
MP/IL - 10 with SC/OEG transplants	1765
MP/IL	1765
10 with SC/OEG transplants	1772
10	1772
SC/OEG transplants	1780
gross locomotor performance -LRB- BBB scores -RRB-	1822
gross locomotor performance	1822
BBB scores	1851
injury-only controls	1868
MP/IL -10 given prior to SC-only transplants	1890
MP/IL -10	1890
SC-only transplants	1914
behavioral outcome	1953
beneficial effects of MP/IL -10	1981
beneficial effects	1981
MP/IL -10	2003
cell transplantation	2056
we	2078
tissue protective agents	2108
the milieu of the injured spinal cord	2147
the milieu	2147
the injured spinal cord	2161
the benefit or detriment of later transplanted cells	2188
the benefit or detriment	2188
later transplanted cells	2216
neuroprotectants	2257
the time of cell grafting or less invasive transplantation techniques employed to reduce damage to tissue spared by an earlier protection strategy	2304
the time of cell grafting	2304
the time	2304
cell grafting	2316
less invasive transplantation techniques employed to reduce damage to tissue spared by an earlier protection strategy	2333
less invasive transplantation techniques	2333
damage	2393
tissue spared by an earlier protection strategy	2403
tissue	2403
an earlier protection strategy	2420
INTRODUCTION TRAUMA TO THE SPINAL CORD	2453
INTRODUCTION TRAUMA TO	2453
INTRODUCTION TRAUMA	2453
THE SPINAL CORD	2476
both an immediate mechanical and irreversible disruption of cellular and axonal integrity and a later initiation of a cascade of processes responsible for progressive neural damage , termed Òsecondary injuryÓ -LRB- Schwab and Bartholdi , 1996 ; Amar and Levy , 1999 -RRB-	2501
an immediate mechanical and irreversible disruption of cellular and axonal integrity	2506
an immediate mechanical and irreversible disruption	2506
cellular and axonal integrity	2561
a later initiation of a cascade of processes responsible for progressive neural damage , termed Òsecondary injuryÓ -LRB- Schwab and Bartholdi , 1996 ; Amar and Levy , 1999 -RRB-	2595
a later initiation of a cascade of processes	2595
a later initiation	2595
a cascade of processes	2617
a cascade	2617
processes	2630
progressive neural damage	2656
Òsecondary injuryÓ -LRB- Schwab and Bartholdi , 1996 ; Amar and Levy , 1999 -RRB-	2690
Òsecondary injuryÓ	2690
Schwab and Bartholdi , 1996 ; Amar and Levy , 1999	2710
Schwab and Bartholdi	2710
1996 ; Amar and Levy	2732
1996	2732
Amar and Levy	2738
1999	2753
Therapies for spinal cord injury	2760
Therapies	2760
spinal cord injury	2774
two directions : -LRB- i -RRB- the use of protective regimens to limit expansion of the secondary injury and -LRB- ii -RRB- the employment of regenerative / reparative strategies aimed at replacing missing tissue and restoring lost connections and function	2826
two directions	2826
-LRB- i -RRB- the use of protective regimens to limit expansion of the secondary injury and -LRB- ii -RRB- the employment of regenerative / reparative strategies aimed at replacing missing tissue and restoring lost connections and function	2842
the use	2846
protective regimens to limit expansion of the secondary injury and -LRB- ii -RRB- the employment of regenerative / reparative strategies aimed at replacing missing tissue and restoring lost connections and function	2857
expansion of the secondary injury and -LRB- ii -RRB- the employment of regenerative	2886
expansion	2886
the secondary injury and -LRB- ii -RRB- the employment of regenerative	2899
the secondary injury	2899
ii	2925
the employment of regenerative	2929
the employment	2929
reparative strategies aimed at replacing missing tissue and restoring lost connections and function	2961
reparative strategies	2961
tissue	3010
lost connections and function	3031
Methylprednisolone -LRB- MP -RRB- , an anti-inflammatory glucocorticosteroid ,	3062
Methylprednisolone -LRB- MP -RRB-	3062
Methylprednisolone	3062
MP	3082
an anti-inflammatory glucocorticosteroid	3087
one such protective drug that has made its way into the clinic , recommended for use acutely following SCI in the United States	3132
one such protective drug	3132
its way	3171
the clinic , recommended for use acutely following SCI in the United States	3184
the clinic	3184
use	3212
SCI in the United States	3234
SCI	3234
the United States	3241
It	3260
the degree of behavioral deficits	3303
the degree	3303
behavioral deficits	3317
experimental models of SCI -LRB- Braughler et al. , 1987 ; Behrmann et al. , 1994 -RRB-	3340
experimental models	3340
SCI -LRB- Braughler et al. , 1987 ; Behrmann et al. , 1994 -RRB-	3363
SCI	3363
Braughler	3368
et al. , 1987 ; Behrmann et al. , 1994	3378
et al.	3378
1987 ; Behrmann et al.	3386
1987	3386
Behrmann et al.	3392
Behrmann	3392
et al.	3401
1994	3409
the mechanism by which MP is protective	3425
the mechanism	3425
MP	3448
an open question	3474
some debate also about its long-term benefit in the clinical setting -LRB- Nesathurai , 1998 ; Hurlbert , 2000 ; Short et al. , 2000 -RRB-	3497
some debate	3497
its long-term benefit in the clinical setting -LRB- Nesathurai , 1998 ; Hurlbert , 2000 ; Short et al. , 2000 -RRB-	3520
its long-term benefit	3520
the clinical setting -LRB- Nesathurai , 1998 ; Hurlbert , 2000 ; Short et al. , 2000 -RRB-	3545
the clinical setting	3545
Nesathurai , 1998 ; Hurlbert , 2000 ; Short et al. , 2000	3567
Nesathurai	3567
1998 ; Hurlbert , 2000 ; Short et al.	3579
1998	3579
Hurlbert , 2000 ; Short et al.	3585
Hurlbert , 2000	3585
Hurlbert	3585
2000	3595
Short et al.	3601
Short	3601
et al.	3607
2000	3615
rat models of SCI	3625
rat models	3625
SCI	3639
MP administration	3644
the accumulation of immune cells	3673
the accumulation	3673
immune cells	3693
the lesion site -LRB- Bartholdi and Schwab , 1995 ; Oudega et al. , 1999 -RRB-	3713
the lesion site	3713
Bartholdi and Schwab , 1995 ; Oudega et al. , 1999	3730
Bartholdi and Schwab	3730
1995 ; Oudega et al.	3752
1995	3752
Oudega et al.	3758
Oudega	3758
et al.	3765
1999	3773
tissue loss and axonal dieback -LRB- Chen et al. , 1996 ; Oudega et al. , 1999 -RRB-	3791
tissue loss and axonal dieback	3791
Chen	3823
et al. , 1996 ; Oudega et al. , 1999	3828
et al.	3828
1996 ; Oudega et al.	3836
1996	3836
Oudega et al.	3842
Oudega	3842
et al.	3849
1999	3857
Interleukin-10 -LRB- IL-10 -RRB-	3864
Interleukin-10	3864
IL-10	3880
another potent anti-inflammatory molecule that is capable of reducing tissue loss in several models of CNS injury -LRB- Knoblach and Faden , 1998 ; Brewer et al. , 1999 ; Plunkett et al. , 2001 -RRB-	3890
another potent anti-inflammatory molecule	3890
tissue loss	3960
several models of CNS injury -LRB- Knoblach and Faden , 1998 ; Brewer et al. , 1999 ; Plunkett et al. , 2001 -RRB-	3975
several models	3975
CNS injury -LRB- Knoblach and Faden , 1998 ; Brewer et al. , 1999 ; Plunkett et al. , 2001 -RRB-	3993
CNS injury	3993
Knoblach and Faden , 1998 ; Brewer et al. , 1999 ; Plunkett et al. , 2001	4005
Knoblach and Faden	4005
Knoblach	4005
Faden	4018
1998 ; Brewer et al.	4025
1998	4025
Brewer et al.	4031
Brewer	4031
et al.	4038
1999 ; Plunkett et al. , 2001	4046
1999	4046
Plunkett et al. , 2001	4052
Plunkett	4052
et al. , 2001	4061
et al.	4061
2001	4069
The systemic administration of IL-10	4076
The systemic administration	4076
IL-10	4107
SCI	4127
tissue loss	4182
open-field locomotion -LRB- Bethea et al. , 1999 -RRB-	4206
open-field locomotion	4206
Bethea	4229
et al. , 1999	4236
et al.	4236
1999	4244
We	4251
MP and IL-10	4300
spinal cord contusion	4319
there	4342
significant enhancement of tissue sparing over either compound administered alone -LRB- Takami et al. , 2002a -RRB-	4351
significant enhancement	4351
tissue sparing over either compound administered alone -LRB- Takami et al. , 2002a -RRB-	4378
tissue sparing	4378
either compound administered alone	4398
either compound	4398
Takami	4434
et al. , 2002a	4441
et al.	4441
2002a	4449
the acute administration of MP -LRB- Oudega et al. , 1999 ; Takami et al. , 2002a -RRB- and IL-10 -LRB- Bethea et al. , 1999 ; Takami et al. , 2002a -RRB-	4466
the acute administration	4466
MP -LRB- Oudega et al. , 1999 ; Takami et al. , 2002a -RRB- and IL-10 -LRB- Bethea et al. , 1999 ; Takami et al. , 2002a -RRB-	4494
MP	4494
Oudega	4498
et al. , 1999 ; Takami et al. , 2002a	4505
et al.	4505
1999 ; Takami et al.	4513
1999	4513
Takami et al.	4519
Takami	4519
et al.	4526
2002a	4534
IL-10	4545
Bethea	4552
et al. , 1999 ; Takami et al. , 2002a	4559
et al.	4559
1999 ; Takami et al.	4567
1999	4567
Takami et al.	4573
Takami	4573
et al.	4580
2002a	4588
injury-induced tissue damage	4603
SCI	4638
severe	4643
functional deficits persist	4650
functional deficits	4650
Takami et al. , 2002a	4679
Takami	4679
et al.	4686
2002a	4694
functional restitution	4722
additional repair strategies	4746
lost cells	4803
regeneration of damaged axons for re-connection to their appropriate targets	4829
regeneration	4829
damaged axons for re-connection to their appropriate targets	4845
damaged axons	4845
re-connection to their appropriate targets	4863
re-connection	4863
their appropriate targets	4880
Cellular grafting strategies with various cell types	4907
Cellular grafting strategies	4907
various cell types	4941
an ability to produce improvements in behavioral recovery after SCI -LRB- Li et al. , 1997 ; Liu et al. , 1999 ; McDonald et al. , 1999 ; Ram -- n-Cueto et al. , 2000 ; Takami et al. , 2002b -RRB-	4978
improvements in behavioral recovery	5000
improvements	5000
behavioral recovery	5016
SCI -LRB- Li et al. , 1997 ; Liu et al. , 1999 ; McDonald et al. , 1999 ; Ram -- n-Cueto et al. , 2000 ; Takami et al. , 2002b -RRB-	5042
SCI	5042
Li et al. , 1997 ; Liu et al. , 1999 ; McDonald et al. , 1999 ; Ram -- n-Cueto et al. , 2000 ; Takami et al. , 2002b	5047
Li	5047
et al. , 1997 ; Liu et al. , 1999 ; McDonald et al. , 1999 ; Ram -- n-Cueto et al. , 2000 ; Takami et al. , 2002b	5050
et al. , 1997	5050
et al.	5050
1997	5058
Liu et al. , 1999	5064
Liu	5064
et al. , 1999	5068
et al.	5068
1999	5076
McDonald et al. , 1999	5082
McDonald	5082
et al. , 1999	5091
et al.	5091
1999	5099
Ram -- n-Cueto et al. , 2000	5105
Ram	5105
n-Cueto et al. , 2000	5109
et al. , 2000	5117
et al.	5117
2000	5125
Takami et al. , 2002b	5131
Takami	5131
et al. , 2002b	5138
et al.	5138
2002b	5146
A well-studied and frequently employed cell type for SCI repair	5154
A well-studied and frequently employed cell type	5154
SCI repair	5207
the Schwann cell -LRB- SC -RRB- , a myelinating glial cell of the peripheral nervous system that promotes regeneration of propriospinal neurons -LRB- Xu et al. , 1995a , 1997 , 1999 ; Guest et al. , 1997 -RRB- and brainstem neurons -LRB- in the presence of neurotrophic factors -RRB- -LRB- Xu et al. , 1995b ; Menei et al. , 1998 ; Bamber et al. , 2001 -RRB- after grafting into the injured spinal cord	5221
the Schwann cell -LRB- SC -RRB-	5221
the Schwann cell	5221
SC	5239
a myelinating glial cell of the peripheral nervous system that promotes regeneration of propriospinal neurons -LRB- Xu et al. , 1995a , 1997 , 1999 ; Guest et al. , 1997 -RRB- and brainstem neurons -LRB- in the presence of neurotrophic factors -RRB- -LRB- Xu et al. , 1995b ; Menei et al. , 1998 ; Bamber et al. , 2001 -RRB- after grafting into the injured spinal cord	5244
a myelinating glial cell	5244
the peripheral nervous system that promotes regeneration of propriospinal neurons -LRB- Xu et al. , 1995a , 1997 , 1999 ; Guest et al. , 1997 -RRB- and brainstem neurons -LRB- in the presence of neurotrophic factors -RRB- -LRB- Xu et al. , 1995b ; Menei et al. , 1998 ; Bamber et al. , 2001 -RRB- after grafting into the injured spinal cord	5272
the peripheral nervous system	5272
regeneration of propriospinal neurons -LRB- Xu et al. , 1995a , 1997 , 1999 ; Guest et al. , 1997 -RRB- and brainstem neurons -LRB- in the presence of neurotrophic factors -RRB- -LRB- Xu et al. , 1995b ; Menei et al. , 1998 ; Bamber et al. , 2001 -RRB-	5316
regeneration	5316
propriospinal neurons -LRB- Xu et al. , 1995a , 1997 , 1999 ; Guest et al. , 1997 -RRB- and brainstem neurons -LRB- in the presence of neurotrophic factors -RRB-	5332
propriospinal neurons	5332
Xu et al. , 1995a , 1997 , 1999 ; Guest et al. , 1997	5355
Xu	5355
et al. , 1995a , 1997 , 1999 ; Guest et al. , 1997	5358
et al.	5358
1995a	5366
1997	5373
1999 ; Guest et al.	5379
1999	5379
Guest et al.	5385
Guest	5385
et al.	5391
1997	5399
brainstem neurons	5409
the presence of neurotrophic factors	5431
the presence	5431
neurotrophic factors	5447
Xu et al. , 1995b ; Menei et al. , 1998 ; Bamber et al. , 2001	5470
Xu	5470
et al. , 1995b ; Menei et al. , 1998 ; Bamber et al. , 2001	5473
et al. , 1995b	5473
et al.	5473
1995b	5481
Menei et al. , 1998	5488
Menei	5488
et al. , 1998	5494
et al.	5494
1998	5502
Bamber et al. , 2001	5508
Bamber	5508
et al. , 2001	5515
et al.	5515
2001	5523
the injured spinal cord	5549
The olfactory ensheathing glial cell -LRB- OEG -RRB-	5574
The olfactory ensheathing glial cell	5574
OEG	5612
another cell type that has shown promise in repair of the injured spinal cord -LRB- Li et al. , 1997 , 1998 ; Ram -- n-Cueto et al. , 1998 , 2000 ; Takami et al. , 2002b -RRB- , displaying in particular an ability to facilitate long-tract regeneration and behavioral recovery in a complete transection model -LRB- Ram -- n-Cueto et al. , 2000 -RRB-	5620
another cell type	5620
promise in repair of the injured spinal cord -LRB- Li et al. , 1997 , 1998 ; Ram -- n-Cueto et al. , 1998 , 2000 ; Takami et al. , 2002b -RRB-	5653
promise	5653
repair of the injured spinal cord -LRB- Li et al. , 1997 , 1998 ; Ram -- n-Cueto et al. , 1998 , 2000 ; Takami et al. , 2002b -RRB-	5664
repair	5664
the injured spinal cord -LRB- Li et al. , 1997 , 1998 ; Ram -- n-Cueto et al. , 1998 , 2000 ; Takami et al. , 2002b -RRB-	5674
the injured spinal cord	5674
Li	5699
et al. , 1997 , 1998 ; Ram -- n-Cueto et al. , 1998 , 2000 ; Takami et al. , 2002b	5702
et al.	5702
1997 , 1998 ; Ram -- n-Cueto et al. , 1998 , 2000 ; Takami et al.	5710
1997 , 1998	5710
1997	5710
1998	5716
Ram -- n-Cueto et al. , 1998 , 2000	5722
Ram -- n-Cueto et al. , 1998	5722
Ram	5722
et al. , 1998	5734
et al.	5734
1998	5742
2000	5748
Takami et al.	5754
Takami	5754
et al.	5761
2002b	5769
particular an ability	5791
long-tract regeneration and behavioral recovery in a complete transection model -LRB- Ram -- n-Cueto et al. , 2000 -RRB-	5827
long-tract regeneration and behavioral recovery	5827
a complete transection model -LRB- Ram -- n-Cueto et al. , 2000 -RRB-	5878
a complete transection model	5878
Ram	5908
n-Cueto et al. , 2000	5912
n-Cueto	5912
et al.	5920
2000	5928
a SC bridge	5958
OEG implanted into the host spinal cord stumps after complete transection	5975
OEG	5975
the host spinal cord stumps	5994
complete transection	6028
regeneration of both descending and ascending axons into the caudal and rostral cord , respectively -LRB- Ram -- n-Cueto et al. , 1998 -RRB-	6058
regeneration	6058
both	6074
axons	6104
the caudal and rostral cord , respectively	6115
the caudal and rostral cord	6115
Ram	6158
n-Cueto et al. , 1998	6162
n-Cueto	6162
et al.	6170
1998	6178
the current study	6188
we	6207
combined MP and IL-10	6222
the efficacy of rat SC or SC/OEG grafts	6259
the efficacy	6259
rat SC or SC/OEG grafts	6275
behavioral recovery following transplantation at 1 week after moderate contusive injury , a model that mirrors a common form of human SCI -LRB- Bunge et al. , 1997 ; Kakulas , 1999 -RRB-	6310
behavioral recovery following transplantation at 1 week after moderate contusive injury	6310
behavioral recovery following transplantation	6310
1 week after moderate contusive injury	6359
1 week	6359
moderate contusive injury	6372
a model that mirrors a common form of human SCI -LRB- Bunge et al. , 1997 ; Kakulas , 1999 -RRB-	6399
a model	6399
a common form of human SCI	6420
a common form	6420
human SCI	6437
Bunge	6448
et al. , 1997 ; Kakulas , 1999	6454
et al.	6454
1997 ; Kakulas	6462
1997	6462
Kakulas	6468
1999	6477
MATERIALS AND METHODS Cultures Schwann cells .	6485
MATERIALS AND METHODS	6485
MATERIALS	6485
METHODS	6499
Cultures Schwann cells	6507
Cultures	6507
Schwann cells	6516
SCs	6531
sciatic nerves of adult female Fischer rats -LRB- Harlan Co , Indianapolis , IN -RRB- as described previously -LRB- Morrissey et al. , 1991 -RRB-	6554
sciatic nerves	6554
adult female Fischer rats -LRB- Harlan Co , Indianapolis , IN -RRB- as described previously -LRB- Morrissey et al. , 1991 -RRB-	6572
adult female Fischer rats -LRB- Harlan Co , Indianapolis , IN -RRB-	6572
adult female Fischer rats	6572
Harlan Co , Indianapolis	6599
Harlan Co	6599
Indianapolis	6610
Morrissey	6653
et al. , 1991	6663
et al.	6663
1991	6671
the nerves	6687
culture dishes in DMEM/10 % heat inactivated fetal bovine serum -LRB- FBS -RRB- without mitogens	6724
culture dishes	6724
DMEM/10 % heat inactivated fetal bovine serum -LRB- FBS -RRB- without mitogens	6742
DMEM/10 %	6742
heat	6751
fetal bovine serum -LRB- FBS -RRB-	6768
fetal bovine serum	6768
FBS	6788
mitogens	6801
Two weeks later	6811
outward migration of fibroblasts	6834
outward migration	6834
fibroblasts	6855
the explants	6868
new dishes where they were enzymatically dissociated and then re-plated in DMEM/10 % FBS supplemented with three mitogens , bovine pituitary extract -LRB- 2 mg/mL , Invitrogen Corporation , Carlsbad , CA -RRB- , forskolin -LRB- 0.8 µg/mL -RRB- , and heregulin -LRB- 2.5 nM , Genentech , San Francisco , CA -RRB- -LRB- Meijs et al. , 2004 -RRB-	6901
new dishes where they were enzymatically dissociated	6901
new dishes	6901
they	6918
then re-plated in DMEM/10 % FBS supplemented with three mitogens , bovine pituitary extract -LRB- 2 mg/mL , Invitrogen Corporation , Carlsbad , CA -RRB- , forskolin -LRB- 0.8 µg/mL -RRB- , and heregulin -LRB- 2.5 nM , Genentech , San Francisco , CA -RRB- -LRB- Meijs et al. , 2004 -RRB-	6958
then re-plated in DMEM/10 % FBS	6958
DMEM/10 %	6976
three mitogens , bovine pituitary extract -LRB- 2 mg/mL , Invitrogen Corporation , Carlsbad , CA -RRB- , forskolin -LRB- 0.8 µg/mL -RRB- , and heregulin -LRB- 2.5 nM , Genentech , San Francisco , CA -RRB- -LRB- Meijs et al. , 2004 -RRB-	7007
three mitogens	7007
bovine pituitary extract -LRB- 2 mg/mL , Invitrogen Corporation , Carlsbad , CA -RRB- , forskolin -LRB- 0.8 µg/mL -RRB- , and heregulin -LRB- 2.5 nM , Genentech , San Francisco , CA -RRB- -LRB- Meijs et al. , 2004 -RRB-	7023
bovine pituitary extract -LRB- 2 mg/mL , Invitrogen Corporation , Carlsbad , CA -RRB-	7023
bovine pituitary extract	7023
2 mg/mL	7049
Invitrogen Corporation	7058
Carlsbad , CA	7082
forskolin -LRB- 0.8 µg/mL -RRB-	7097
forskolin	7097
0.8 µg/mL	7108
heregulin -LRB- 2.5 nM , Genentech , San Francisco , CA -RRB- -LRB- Meijs et al. , 2004 -RRB-	7124
heregulin -LRB- 2.5 nM , Genentech , San Francisco , CA -RRB-	7124
heregulin	7124
2.5 nM , Genentech , San Francisco , CA	7135
2.5 nM	7135
Genentech	7143
San Francisco	7154
CA	7169
Meijs	7174
et al. , 2004	7180
et al.	7180
2004	7188
Cells	7195
confluency	7215
new dishes	7242
three times	7253
Their purity for grafting	7266
Their purity	7266
grafting	7283
a method described earlier -LRB- Takami et al. , 2002b -RRB-	7296
a method	7296
earlier -LRB- Takami et al. , 2002b -RRB-	7315
earlier	7315
Takami	7324
et al. , 2002b	7331
et al.	7331
2002b	7339
95-98 %	7363
Olfactory ensheathing glia	7371
cultures of OEG	7415
cultures	7415
OEG	7427
the nerve fiber	7450
layer of the olfactory bulb of adult female Fischer rats -LRB- Harlan Co -RRB- using a procedure modified from one described previously -LRB- Ram -- n-Cueto et al. , 1998 -RRB-	7466
layer	7466
the olfactory bulb	7475
adult female Fischer rats	7497
Harlan Co	7524
a procedure modified from one described previously -LRB- Ram -- n-Cueto et al. , 1998 -RRB-	7541
a procedure modified from one described previously	7541
a procedure	7541
one described previously	7567
one	7567
Ram	7593
n-Cueto et al. , 1998	7597
n-Cueto	7597
et al.	7605
1998	7613
Care	7620
the inclusion of non-nerve fiber layer bulb tissue	7647
the inclusion	7647
non-nerve fiber layer bulb tissue	7664
the pia	7703
OEG	7724
the Ram -- n-Cueto	7757
the Ram	7757
n-Cueto	7765
et al. -LRB- 1998 -RRB- method ,	7773
et al.	7773
1998	7781
method	7787
5 days to forskolin -LRB- 0.8 µg/mL -RRB- and pituitary extract -LRB- 2 µg/mL -RRB- in DMEM/F12/10 % FBS before purification	7812
5 days	7812
forskolin -LRB- 0.8 µg/mL -RRB- and pituitary extract -LRB- 2 µg/mL -RRB-	7822
forskolin	7822
0.8 µg/mL	7833
pituitary extract	7848
2 µg/mL	7867
DMEM/F12/10 % FBS before purification	7879
DMEM/F12/10 % FBS	7879
purification	7903
p75 immuno-panning	7919
Takami	7954
et al. -LRB- 2002b -RRB-	7961
et al.	7961
2002b	7969
A second period in mitogens	7977
A second period	7977
mitogens	7996
confluency for transplantation	8028
confluency	8028
transplantation	8043
the purity	8069
SCs except that p75 rather than S100	8095
SCs	8095
that p75 rather than S100	8106
that p75	8106
S100	8127
Hoechst nuclear staining	8146
Purity	8172
94-98 %	8195
Animals Adult female Fischer rats -LRB- Harlan Co. , n = 92 ; 160-180 g -RRB-	8203
Animals Adult female Fischer rats	8203
Animals	8203
Adult female Fischer rats	8211
Harlan Co. , n = 92 ; 160-180 g	8238
Harlan Co.	8238
n = 92 ; 160-180 g	8250
n = 92	8250
n	8250
92	8254
160-180 g	8258
NIH and USDA guidelines	8294
The Institutional Animal Care and Use Committee of the University of Miami	8319
The Institutional Animal Care and Use Committee	8319
the University of Miami	8370
the University	8370
Miami	8388
all animal procedures	8403
The rats	8426
anesthetized with 1Ð2 % halothane	8440
1Ð2 %	8458
a mixture of 70 % nitrous oxide and 30 % oxygen	8476
a mixture	8476
70 % nitrous oxide and 30 % oxygen	8489
70 % nitrous oxide	8489
30 % oxygen	8511
An adequate level of anesthesia	8523
An adequate level	8523
anesthesia	8544
the corneal reflex and withdrawal	8584
the corneal reflex	8584
withdrawal	8607
painful stimuli for the hindlimbs	8621
painful stimuli	8621
the hindlimbs	8641
The back region	8656
betadine	8713
Lacrilube ophthalmic ointment -LRB- Allergan Pharmaceuticals , Irvine , CA -RRB-	8723
Lacrilube ophthalmic ointment	8723
Allergan Pharmaceuticals	8754
Irvine	8780
CA	8788
the eyes	8807
bicillin -LRB- 0.02 mL/100 mg body weight , 300 U/mL , i.m. ; J. Buck , Inc. , Owings Mills , MO -RRB-	8839
bicillin	8839
0.02 mL/100	8849
mg body weight , 300 U/mL , i.m. ; J. Buck , Inc. , Owings Mills , MO	8861
mg body weight	8861
300 U/mL	8877
i.m.	8887
J. Buck , Inc. , Owings Mills , MO	8893
surgery	8963
the rats	8972
a heating pad	8994
the body temperature	9020
37 ± 0.5 °C	9044
37 ±	9044
0.5 °C	9049
Contusion injury .	9056
Contusion	9056
injury	9066
Contusion injury	9074
the weight drop device	9106
New	9142
York University -LRB- Gruner , 1992 -RRB-	9146
York University	9146
Gruner	9163
1992	9171
anesthesia	9188
a vertical incision	9200
the thoracic vertebra and the superficial muscle	9235
the thoracic vertebra	9235
the superficial muscle	9261
skin	9288
A laminectomy performed at thoracic vertebra T8	9304
A laminectomy	9304
thoracic vertebra T8	9331
the dorsal surface of the spinal cord	9360
the dorsal surface	9360
the spinal cord	9382
-LRB- T9 -RRB- without disrupting the dura mater	9409
-LRB- T9 -RRB-	9409
the dura mater	9433
Stabilization clamps	9449
the vertebrae at T6 and T12	9489
the vertebrae	9489
T6 and T12	9506
the column	9528
impact	9546
The exposed spinal cord	9554
a 10.0-g rod	9613
a height of 12.5 mm	9631
a height	9631
12.5 mm	9643
The contusion impact height , velocity and compression	9652
The contusion impact height	9652
velocity	9681
compression	9694
Animals -LRB- n = 4 -RRB-	9722
Animals	9722
n	9731
4	9735
height or velocity errors	9769
6 %	9804
the compression distance	9813
the range of 1.35-1.75 mm	9853
the range	9853
1.35-1.75 mm	9866
injury	9886
the muscles	9894
layers	9922
the skin	9933
metal wound clips	9954
The rats	9973
a warmed cage with water and food easily accessible	10009
a warmed cage	10009
water and food	10028
Bicillin	10062
2 , 4 , and 6 days	10097
2	10097
4	10100
6 days	10107
injury	10120
The rats	10128
12 weeks	10157
injury	10172
Administration of methylprednisolone and interleukin - 10 .	10180
Administration of methylprednisolone and interleukin	10180
Administration	10180
methylprednisolone and interleukin	10198
10	10234
MP sodium succinate intravenously -LRB- Upjohn Company , Kalamazoo , MI -RRB-	10261
MP sodium succinate intravenously	10261
MP sodium succinate	10261
Upjohn Company	10296
Kalamazoo	10312
MI	10323
a small incision	10328
the right ventral neck region before injury	10357
the right ventral neck region	10357
injury	10394
the jugular vein	10411
A polyethylene tube -LRB- PE-50 , 0.28 mm I.D. ; Clay Adams , Parsippany , NJ -RRB- filled with saline	10429
A polyethylene tube -LRB- PE-50 , 0.28 mm I.D. ; Clay Adams , Parsippany , NJ -RRB-	10429
A polyethylene tube	10429
PE-50 , 0.28 mm I.D. ; Clay Adams , Parsippany , NJ	10450
PE-50	10450
0.28 mm I.D. ; Clay Adams	10457
0.28 mm I.D.	10457
Clay Adams	10471
Parsippany , NJ	10483
saline	10511
3-5 mm	10536
the vein	10548
7-0 silk sutures	10577
The free end of the tube	10595
The free end	10595
the tube	10611
the skin	10637
the shoulder to leave the body through a small opening in the dorsal neck region -LRB- Chen et al. , 1996 ; Oudega et al. , 1999 -RRB-	10655
the body	10677
a small opening in the dorsal neck region -LRB- Chen et al. , 1996 ; Oudega et al. , 1999 -RRB-	10694
a small opening	10694
the dorsal neck region -LRB- Chen et al. , 1996 ; Oudega et al. , 1999 -RRB-	10713
the dorsal neck region	10713
Chen	10737
et al. , 1996 ; Oudega et al. , 1999	10742
et al.	10742
1996 ; Oudega et al.	10750
1996	10750
Oudega et al.	10756
Oudega	10756
et al.	10763
1999	10771
contusion	10788
MP -LRB- 30 mg/kg body weight -RRB- was administered intravenously -LRB- i.v. -RRB- at 5 minutes and the animals	10799
MP	10799
30 mg/kg body weight	10803
i.v.	10857
5 minutes and the animals	10866
5 minutes	10866
the animals	10880
their cages	10909
MP	10933
catheter at 2	10963
catheter	10963
2	10975
4 hours	10981
IL	11002
10 -LRB- 30 mg/kg of recombinant human IL-10 , gift of Shering - Plough Pharmaceuticals , Kenilworth , NJ -RRB-	11006
10	11006
30 mg/kg of recombinant human IL-10 , gift of Shering - Plough Pharmaceuticals , Kenilworth , NJ	11010
30 mg/kg	11010
recombinant human IL-10 , gift of Shering - Plough Pharmaceuticals , Kenilworth , NJ	11022
recombinant human IL-10	11022
gift of Shering - Plough Pharmaceuticals , Kenilworth , NJ	11047
gift of Shering	11047
gift	11047
Plough Pharmaceuticals , Kenilworth , NJ	11064
Plough Pharmaceuticals	11064
Kenilworth , NJ	11088
these animals intraperitoneally -LRB- i.p. -RRB-	11129
these animals intraperitoneally	11129
these animals	11129
30 minutes	11168
injury	11185
Controls	11193
lactated RingerÕs solution both i.v. at 5 minutes , and 2 and 4 hours post-injury and i.p.	11225
lactated RingerÕs solution	11225
i.v. at 5 minutes	11257
i.v.	11257
5 minutes	11265
2 and 4 hours	11280
30 minutes after injury	11318
30 minutes	11318
injury	11335
Rats	11343
six experimental groups : injured-only control -LRB- n = 15 -RRB- ; MP/IL -10 -LRB- n = 13 -RRB- ; SC grafted -LRB- n = 14 -RRB- ; MP/IL -10 1 SC grafted -LRB- n = 13 -RRB- ; SC/OEG grafted -LRB- n = 13 -RRB- ; MP/IL -10 1 SC/OEG grafted -LRB- n = 14 -RRB-	11366
six experimental groups : injured-only control -LRB- n = 15 -RRB- ; MP/IL -10 -LRB- n = 13 -RRB- ; SC grafted -LRB- n = 14 -RRB- ; MP/IL -10 1 SC grafted -LRB- n = 13 -RRB-	11366
six experimental groups : injured-only control -LRB- n = 15 -RRB- ; MP/IL -10 -LRB- n = 13 -RRB- ; SC grafted -LRB- n = 14 -RRB- ; MP/IL -10 1 SC grafted	11366
six experimental groups	11366
injured-only control -LRB- n = 15 -RRB- ; MP/IL -10 -LRB- n = 13 -RRB- ; SC grafted -LRB- n = 14 -RRB- ; MP/IL -10 1 SC grafted	11391
control -LRB- n = 15 -RRB- ; MP/IL -10 -LRB- n = 13 -RRB- ; SC grafted -LRB- n = 14 -RRB-	11404
control -LRB- n = 15 -RRB- ; MP/IL -10 -LRB- n = 13 -RRB-	11404
control -LRB- n = 15 -RRB-	11404
control	11404
n	11413
15	11417
MP/IL -10 -LRB- n = 13 -RRB-	11422
MP/IL -10	11422
n	11432
13	11436
SC grafted -LRB- n = 14 -RRB-	11441
SC	11441
n = 14	11453
n	11453
= 14	11455
MP/IL -10 1 SC grafted	11462
MP/IL -10 1 SC	11462
MP/IL -10	11462
1 SC	11471
n	11485
13	11489
SC/OEG grafted -LRB- n = 13 -RRB-	11494
SC/OEG	11494
n = 13	11510
n	11510
= 13	11512
MP/IL -10 1 SC/OEG grafted -LRB- n = 14 -RRB-	11519
MP/IL -10 1 SC/OEG	11519
MP/IL -10	11519
1 SC/OEG	11528
n = 14	11546
n	11546
= 14	11548
these groups	11560
five rats	11574
anterograde tracing , five for retrograde tracing and five for volume analysis and immunochemistry	11598
anterograde	11598
five	11619
and five for volume analysis and immunochemistry	11647
and five	11647
volume analysis and immunochemistry	11660
some treatment groups , less than five , but at least three	11700
some treatment groups , less than five	11700
some treatment groups	11700
less than five	11723
at least three	11743
animals per group	11759
animals	11759
group	11771
analysis	11811
some	11828
one or more of the three tracers in the brain -LRB- n = 8 of 30 animals -RRB-	11884
one or more	11884
the three tracers in the brain -LRB- n = 8 of 30 animals -RRB-	11899
the three tracers	11899
the brain -LRB- n = 8 of 30 animals -RRB-	11920
the brain	11920
n = 8 of 30 animals	11931
n = 8	11931
n	11931
8	11935
30 animals	11940
All animals	11953
8 weeks of behavioral testing	11974
8 weeks	11974
behavioral testing	11985
One week	12022
injury	12037
rats	12045
2 % halothane	12075
the injury site	12089
a total of either -LRB- i -RRB- 2 x 10 ^ 6 SCs or -LRB- ii -RRB- 1 x10 ^ 6 SCs and 1 x10 ^ 6 OEG , in 6 µL of DMEM-F12 medium -LRB- Takami et al. , 2002b -RRB-	12122
a total of either -LRB- i -RRB- 2 x 10 ^ 6 SCs or -LRB- ii -RRB- 1 x10 ^ 6 SCs and 1 x10 ^ 6 OEG , in 6 µL of DMEM-F12 medium	12122
a total of either -LRB- i -RRB- 2 x 10 ^ 6 SCs or -LRB- ii -RRB- 1 x10 ^ 6 SCs and 1 x10 ^	12122
a total	12122
either -LRB- i -RRB- 2 x 10 ^ 6 SCs or -LRB- ii -RRB- 1 x10 ^ 6 SCs and 1 x10 ^	12133
-LRB- i -RRB- 2 x 10 ^ 6 SCs or -LRB- ii -RRB- 1 x10 ^ 6 SCs	12140
-LRB- i -RRB- 2	12140
-LRB- i -RRB-	12140
2	12144
10 ^ 6 SCs or -LRB- ii -RRB- 1 x10 ^ 6 SCs	12148
10 ^ 6 SCs	12148
10	12148
6 SCs	12151
ii	12161
1 x10 ^ 6 SCs	12165
1 x10	12165
6 SCs	12171
1 x10 ^	12181
6 µL of DMEM-F12 medium	12197
6 µL	12197
DMEM-F12 medium	12205
Takami	12222
et al. , 2002b	12229
et al.	12229
2002b	12237
the epicenter of the contused area	12263
the epicenter	12263
the contused area	12280
a depth of 1 mm using a 10-µL Hamilton syringe with a pulled , beveled glass pipette tip -LRB- 200 µm diameter -RRB- held in a micromanipulator	12301
a depth	12301
1 mm using a 10-µL Hamilton syringe with a pulled , beveled glass pipette tip -LRB- 200 µm diameter -RRB- held in a micromanipulator	12312
1 mm	12312
a 10-µL Hamilton syringe	12323
a pulled , beveled glass pipette tip -LRB- 200 µm diameter -RRB- held in a micromanipulator	12353
a pulled , beveled glass pipette tip -LRB- 200 µm diameter -RRB-	12353
a pulled , beveled glass pipette tip	12353
200 µm diameter	12390
a micromanipulator	12415
Control rats	12435
6 µL of DMEM-F12 medium	12467
6 µL	12467
DMEM-F12 medium	12475
All injections	12492
a 3-minute period	12527
the injection pipette	12550
place for an additional 3 minutes	12584
place	12584
an additional 3 minutes	12594
leakage	12630
withdrawal	12643
the injections	12661
the muscle layers and the skin	12677
the muscle layers	12677
the skin	12699
Anterograde axonal and retrograde	12732
Anterograde	12732
anterograde tracing	12788
anterograde	12788
9 weeks post-injury rats	12809
9 weeks	12809
2 % halothane	12859
10 % biotinylated dextran amine -LRB- BDA ; Molecular Probes , Eugene , OR -RRB-	12877
10 %	12877
dextran amine	12894
BDA ; Molecular Probes	12909
BDA	12909
Molecular Probes	12914
Eugene , OR	12932
Eugene	12932
OR	12940
the hindlimb area of the motor cortex -LRB- 2 x 0.5 µL -RRB-	12994
the hindlimb area	12994
the motor cortex -LRB- 2 x 0.5 µL -RRB-	13015
the motor cortex	13015
2 x 0.5 µL	13033
2	13033
0.5 µL	13037
10 % dextran-fluorescein -LRB- DFl ; Molecular Probes -RRB-	13046
10 % dextran-fluorescein	13046
DFl ; Molecular Probes	13071
DFl	13071
Molecular Probes	13076
the reticular formation -LRB- 2 x 0.3 µL -RRB-	13099
the reticular formation	13099
2 x 0.3 µL	13124
2	13124
0.3 µL	13128
10 % dextran-rhodamine -LRB- DRh ; Molecular Probes -RRB-	13140
10 % dextran-rhodamine	13140
DRh ; Molecular Probes	13163
DRh	13163
Molecular Probes	13168
the lateral vestibular nuclei -LRB- 2 x 0.2 µL -RRB-	13191
the lateral vestibular nuclei	13191
2 x 0.2 µL	13222
2	13222
0.2 µL	13226
Brains from anterogradely-traced animals	13235
Brains	13235
anterogradely-traced animals	13247
accurate tracer injection	13314
all three areas	13345
each animal	13364
retrograde neuronal tracing	13381
retrograde neuronal	13381
10 weeks after injury rats	13410
10 weeks	13410
injury rats	13425
2 % halothane	13463
A total of 0.5 µL of 2 % aqueous fast blue -LRB- FB ; Sigma -RRB-	13477
A total	13477
0.5 µL of 2 % aqueous fast blue -LRB- FB ; Sigma -RRB-	13488
0.5 µL	13488
2 % aqueous fast blue -LRB- FB ; Sigma -RRB-	13498
2 % aqueous	13498
FB ; Sigma	13520
FB	13520
Sigma	13524
7 mm caudal	13556
the caudal laminectomy edge -LRB- following a small laminectomy between vertebrae T10 and T11 -RRB- using a glass pipette -LRB- diameter , 50 µm -RRB- attached to a 1-µL Hamilton syringe held in a micromanipulator -LRB- Takami et al. , 2002b -RRB-	13571
the caudal laminectomy edge	13571
a small laminectomy between vertebrae T10 and T11	13610
a small laminectomy	13610
vertebrae T10 and T11	13638
vertebrae T10	13638
T11	13656
a glass pipette -LRB- diameter , 50 µm -RRB- attached to a 1-µL Hamilton syringe held in a micromanipulator -LRB- Takami et al. , 2002b -RRB-	13667
a glass pipette	13667
diameter , 50 µm	13684
diameter	13684
50 µm	13694
a 1-µL Hamilton syringe held in a micromanipulator -LRB- Takami et al. , 2002b -RRB-	13713
a 1-µL Hamilton syringe	13713
a micromanipulator -LRB- Takami et al. , 2002b -RRB-	13745
a micromanipulator	13745
Takami	13765
et al. , 2002b	13772
et al.	13772
2002b	13780
All injections	13788
a 3-minute period	13823
the injection pipette	13846
place for an additional 3 minutes	13880
place	13880
an additional 3 minutes	13890
leakage	13926
withdrawal	13939
the injection	13957
the muscles and skin	13972
the muscles	13972
skin	13988
layers	14008
Histology	14016
12 weeks after injury	14029
12 weeks	14029
injury	14044
all rats	14052
2.57 mg ketamine , 0.51 mg xylazine , and 0.09 mg acepromazine per 50 g body weight	14080
2.57 mg ketamine	14080
0.51 mg xylazine	14098
0.09 mg acepromazine per 50 g body weight	14120
0.09 mg acepromazine	14120
50 g body weight	14145
phosphate-buffered , 4 % paraformaldehyde -LRB- 0.1 M , pH 7.4 -RRB- -LRB- Takami et al. , 2002b -RRB-	14196
phosphate-buffered , 4 % paraformaldehyde -LRB- 0.1 M , pH 7.4 -RRB-	14196
phosphate-buffered , 4 % paraformaldehyde	14196
0.1 M	14237
pH 7.4	14244
Takami	14253
et al. , 2002b	14260
et al.	14260
2002b	14268
The T8Ð10 thoracic spinal cord segments -LRB- 9 mm -RRB- , which contained the complete lesion ,	14276
The T8Ð10 thoracic spinal cord segments	14276
9 mm	14317
the complete lesion	14340
either phosphate-buffered 10 % gelatin solution -LRB- Difco Laboratories , Detroit , MI -RRB- -LRB- Oudega et al. , 1994 -RRB-	14392
either phosphate-buffered 10 % gelatin solution -LRB- Difco Laboratories , Detroit , MI -RRB-	14392
either phosphate-buffered 10 % gelatin solution	14392
10 %	14418
Difco Laboratories	14440
Detroit	14460
MI	14469
Oudega	14474
et al. , 1994	14481
et al.	14481
1994	14489
paraffin to prevent further damage during histological procedures	14501
further damage	14521
histological procedures	14543
Gelatin-embedded cord segments	14568
30 µm thick sagittal sections	14613
30 µm	14613
Sections	14684
PBS -LRB- 0.1 M , pH 7.4 -RRB-	14711
PBS	14711
0.1 M	14716
pH 7.4	14723
4 ¡ C	14745
further processing	14755
Gelatin embedding	14775
the tissue	14812
fluorescent tracers and paraffin embedding	14833
fluorescent tracers	14833
paraffin embedding	14857
the intensity of this fluorescence	14887
the intensity	14887
this fluorescence	14904
The brainstem and cerebral cortex	14923
The brainstem	14923
cerebral cortex	14941
30 µm thick transverse sections using a freezing microtome for analysis of retrograde tracing or anterograde tracer injection sites	14971
30 µm thick transverse sections	14971
a freezing microtome	15009
analysis of retrograde tracing or anterograde tracer injection sites	15034
analysis	15034
retrograde tracing or anterograde tracer injection sites	15046
retrograde tracing	15046
anterograde tracer injection sites	15068
Every 10th transverse section	15104
gelatin-coated slides	15151
Vectorshield mounting medium -LRB- Vector Laboratories , Burlingame , CA -RRB-	15195
Vectorshield mounting medium	15195
Vector Laboratories	15225
Burlingame	15246
CA	15258
Paraffin-embedded cord segments	15263
10-µm-thick sagittal sections	15309
histological and immunohistochemical staining	15359
These thinner sections	15406
better study of damaged vs normal-appearing tissue after staining	15437
better study	15437
vs normal-appearing tissue after staining	15461
normal-appearing tissue after staining	15464
normal-appearing tissue	15464
staining	15494
Estimation of volumes .	15504
Estimation	15504
volumes	15518
Every 10th sagittal section of the paraffin-embedded T8Ð10 segmentÑthat	15527
Every 10th sagittal section	15527
the paraffin-embedded T8Ð10 segmentÑthat	15558
every 100-µm interval	15603
the width of the spinal cord -LRB- 14-16 sections per spinal cord -RRB- Ñwas mounted onto slides , stained with haematoxylin , eosin and luxol fast blue , dehydrated , and coverslipped in Pro-Texx mounting medium -LRB- Baxter Diagnostics , Deerfield , IL -RRB- to determine volume -LRB- area 3 section thickness -RRB- using an image analysis computer system -LRB- Universal , West Chester , PA -RRB-	15634
the width	15634
the spinal cord -LRB- 14-16 sections per spinal cord -RRB-	15647
the spinal cord	15647
14-16 sections per spinal cord	15664
14-16 sections	15664
spinal cord	15683
Ñwas	15695
slides , stained with haematoxylin , eosin and luxol fast blue , dehydrated , and coverslipped in Pro-Texx mounting medium -LRB- Baxter Diagnostics , Deerfield , IL -RRB- to determine volume -LRB- area 3 section thickness -RRB- using an image analysis computer system -LRB- Universal , West Chester , PA -RRB-	15713
slides	15713
haematoxylin , eosin and luxol	15734
Pro-Texx	15807
medium -LRB- Baxter Diagnostics , Deerfield , IL -RRB-	15825
medium	15825
Baxter Diagnostics	15833
Deerfield	15853
IL	15864
volume -LRB- area 3 section thickness -RRB- using an image analysis computer system -LRB- Universal , West Chester , PA -RRB-	15881
volume -LRB- area 3 section thickness -RRB-	15881
volume	15881
area 3 section thickness	15889
an image analysis computer system	15921
Universal	15956
West Chester	15967
PA	15981
each section	15989
the total volume of the 9-mm-long cord segment with the lesion epicenter in the middle	16003
the total volume	16003
the 9-mm-long cord segment with the lesion epicenter in the middle	16023
the 9-mm-long cord segment	16023
the lesion epicenter in the middle	16055
the lesion epicenter	16055
the middle	16079
the cavity and damaged tissue volumes	16118
the cavity	16118
damaged tissue volumes	16133
tissue	16181
normal-appearing tissue	16216
an increased density of small -LRB- immune -RRB- cells , fragmented myelin and the absence of healthy appearing neurons	16243
an increased density of small -LRB- immune -RRB- cells , fragmented myelin	16243
an increased density	16243
small -LRB- immune -RRB- cells , fragmented myelin	16267
small -LRB- immune -RRB- cells	16267
the absence of healthy appearing neurons	16311
the absence	16311
healthy appearing neurons	16326
The volumes of each section	16353
The volumes	16353
each section	16368
rat	16397
10	16424
every 10th section	16428
the total volume of the 9-mm-long cord segment and the volumes of cavitated and damaged spinal tissue	16469
the total volume of the 9-mm-long cord segment	16469
the total volume	16469
the 9-mm-long cord segment	16489
the volumes of cavitated and damaged spinal tissue	16520
the volumes	16520
cavitated and damaged spinal tissue	16535
The volume of normal - appearing spinal tissue within the 9-mm-long cord segment	16572
The volume	16572
normal - appearing spinal tissue within the 9-mm-long cord segment	16586
normal	16586
appearing spinal tissue within the 9-mm-long cord segment	16594
appearing spinal tissue	16594
the 9-mm-long cord segment	16625
the added volumes of cavitated and damaged tissue from the volume of the whole cord segment	16682
the added volumes	16682
cavitated and damaged tissue from the volume of the whole cord segment	16703
cavitated and damaged tissue	16703
the volume of the whole cord segment	16737
the volume	16737
the whole cord segment	16751
the total cord volume	16778
cavity , damaged and normal-appearing tissue volumes	16809
cavity	16809
damaged	16817
normal-appearing tissue volumes	16829
this value for normal-appearing tissue	16871
this value	16871
normal-appearing tissue	16886
the percentage of the total volume of the 9 - mm-long cord segment from the same cord level in uninjured rats	16927
the percentage	16927
the total volume of the 9 - mm-long cord segment from the same cord level in uninjured rats	16945
the total volume of the 9	16945
the total volume	16945
the 9	16965
mm-long cord segment from the same cord level in uninjured rats	16972
mm-long cord segment	16972
the same cord level in uninjured rats	16998
the same cord level	16998
uninjured rats	17021
Six uninjured and untreated rats	17037
uninjured	17041
the mean volume of the normal T8Ð10 spinal cord	17108
the mean volume	17108
the normal T8Ð10 spinal cord	17127
Quantitative assessment of traced fibers .	17157
Quantitative assessment	17157
traced fibers	17184
, or DRh-labeled axons	17209
DRh-labeled	17214
every fourth section of the T8Ð10 cord segments -LRB- i.e. , every 120-µm interval spanning the width of the spinal cord -RRB-	17249
every fourth section	17249
the T8Ð10 cord segments	17273
i.e. , every 120-µm interval spanning the width of the spinal cord	17298
i.e.	17298
every 120-µm interval spanning the width of the spinal cord	17304
every 120-µm interval	17304
the width of the spinal cord	17335
the width	17335
the spinal cord	17348
axons	17377
Nickel-enhanced avidinÐbiotinÐperoxidase	17405
staining -LRB- Oudega and Hagg , 1999 -RRB- whereas DFl - and DRh-labeled fibers were detected using fluorescence microscopy	17446
staining	17446
Oudega and Hagg , 1999	17456
Oudega and Hagg	17456
1999	17473
DFl - and DRh-labeled fibers	17487
DFl	17487
DRh-labeled fibers	17496
fluorescence microscopy	17535
The number of labeled axons	17560
The number	17560
labeled axons	17574
all labeled axons crossing imaginary lines placed perpendicular to the rostralÐcaudal cord axis at 2,500 µm rostral and caudal to the epicenter and at the lesion epicenter	17615
all	17615
axons	17627
imaginary lines placed perpendicular to the rostralÐcaudal cord axis at 2,500 µm rostral and caudal to the epicenter and at the lesion epicenter	17642
imaginary lines	17642
perpendicular to the rostralÐcaudal cord axis at 2,500 µm rostral and caudal	17665
the rostralÐcaudal cord axis at 2,500 µm	17682
the rostralÐcaudal cord axis	17682
2,500 µm	17714
the epicenter	17745
the lesion epicenter	17766
The numbers in each section -LRB- 10Ð12 complete sections per spinal cord -RRB-	17788
The numbers	17788
each section -LRB- 10Ð12 complete sections per spinal cord -RRB-	17803
each section	17803
10Ð12 complete sections per spinal cord	17817
10Ð12 complete sections	17817
spinal cord	17845
rat	17874
4	17896
the final number of labeled axons	17908
the final number	17908
labeled axons	17928
numbers of neurons labeled by retrograde tracing	17953
numbers	17953
neurons labeled by retrograde tracing	17964
neurons	17964
retrograde tracing	17983
retrograde	17983
every tenth section	18003
the rat brain atlas -LRB- Paxinos , 1998 -RRB-	18057
the rat brain atlas	18057
Paxinos , 1998	18078
Paxinos	18078
1998	18087
The number of FBlabeled neurons	18094
The number	18094
FBlabeled neurons	18108
the sensorimotor cortex , reticular formation and vestibular nuclei	18141
the sensorimotor cortex	18141
reticular formation	18166
vestibular nuclei	18190
These numbers	18209
the total number of retrogradely-traced neurons calculated for each region according to the following formula : -LSB- -LRB- rostral to caudal length of region -LRB- µm -RRB- / 30 µm -RRB- 3 -LRB- labeled neuron sum/number of sections analyzed for the region -RRB-	18239
the total number of retrogradely-traced neurons calculated for each region according to the following formula : -LSB- -LRB- rostral to caudal length of region -LRB- µm -RRB- / 30 µm -RRB- 3	18239
the total number of retrogradely-traced neurons calculated for each region according to the following formula	18239
the total number	18239
retrogradely-traced neurons calculated for each region according to the following formula	18259
retrogradely-traced neurons	18259
each region	18302
the following formula	18327
-LSB- -LRB- rostral to caudal length of region -LRB- µm -RRB- / 30 µm -RRB- 3	18350
-LSB-	18350
rostral to caudal length of region -LRB- µm -RRB- / 30 µm	18352
rostral	18352
caudal length	18363
region -LRB- µm -RRB- / 30 µm	18380
region -LRB- µm -RRB-	18380
region	18380
µm	18388
30 µm	18392
3	18399
neuron sum/number of sections analyzed for the region	18410
neuron sum/number	18410
sections analyzed for the region	18431
sections	18431
the region	18453
the final summed number of labeled neurons for each region in each animal	18477
the final summed number	18477
labeled neurons for each region in each animal	18504
labeled neurons	18504
each region in each animal	18524
each region	18524
each animal	18539
Immunohistochemistry .	18552
Every tenth sagittal section	18574
mouse monoclonal or rabbit polyclonal antibodies , or both , following an earlier described protocol -LRB- Takami et al. , 2002b -RRB-	18642
mouse monoclonal or rabbit polyclonal antibodies , or both , following an earlier described protocol	18642
rabbit polyclonal antibodies , or both , following an earlier described	18662
rabbit polyclonal antibodies , or both ,	18662
rabbit polyclonal antibodies	18662
both	18695
an earlier described	18711
an earlier	18711
Takami	18742
et al. , 2002b	18749
et al.	18749
2002b	18757
The polyclonal antibodies used	18765
The polyclonal antibodies	18765
anti-serotonin -LRB- 5-HT , 1:500 ; Incstar Corp. , Stillwater , MN -RRB- and anti-glial fibrillary acidic protein -LRB- GFAP , 1:400 ; Dako , Carpinteria , CA -RRB-	18801
anti-serotonin -LRB- 5-HT , 1:500 ; Incstar Corp. , Stillwater , MN -RRB-	18801
anti-serotonin	18801
5-HT , 1:500 ; Incstar Corp. , Stillwater , MN	18817
5-HT	18817
1:500 ; Incstar Corp. , Stillwater	18823
1:500	18823
Incstar Corp. , Stillwater	18830
Incstar Corp.	18830
Stillwater	18845
MN	18857
anti-glial fibrillary acidic protein -LRB- GFAP , 1:400 ; Dako , Carpinteria , CA -RRB-	18865
anti-glial fibrillary acidic protein	18865
GFAP , 1:400 ; Dako , Carpinteria , CA	18903
GFAP	18903
1:400 ; Dako	18909
1:400	18909
Dako	18916
Carpinteria , CA	18922
The monoclonal antibody used	18940
The monoclonal antibody	18940
anti-low-affinity nerve growth factor receptor -LSB- p75 -LRB- 192 IgG -RRB- , 1:2 ; gift from Dr. E. Shooter , Stanford University -RSB-	18973
anti-low-affinity nerve growth factor receptor -LSB- p75 -LRB- 192 IgG -RRB-	18973
anti-low-affinity nerve growth factor receptor	18973
p75 -LRB- 192 IgG -RRB-	19021
p75	19021
192 IgG	19026
1:2	19036
gift from Dr. E. Shooter , Stanford University -RSB-	19041
gift	19041
Dr. E. Shooter , Stanford University -RSB-	19051
Dr. E. Shooter	19051
Stanford University	19067
The secondary antibodies used	19089
The secondary antibodies	19089
Alexa 488-conjugated goat anti-rabbit -LRB- 1:200 ; Molecular Probes -RRB- and Alexa 594-conjugated rabbit anti-mouse -LRB- 1:200 ; Molecular Probes -RRB-	19124
Alexa 488-conjugated goat anti-rabbit -LRB- 1:200 ; Molecular Probes -RRB-	19124
Alexa	19124
488-conjugated goat anti-rabbit -LRB- 1:200 ; Molecular Probes -RRB-	19130
488-conjugated goat anti-rabbit	19130
1:200 ; Molecular Probes	19163
1:200	19163
Molecular Probes	19170
Alexa 594-conjugated rabbit anti-mouse -LRB- 1:200 ; Molecular Probes -RRB-	19192
Alexa 594-conjugated rabbit	19192
1:200 ; Molecular Probes	19232
1:200	19232
Molecular Probes	19239
The sections	19258
gelatin-coated glass slides	19289
Vectorshield	19337
medium	19359
Determination of 5HT fiber growth .	19367
Determination	19367
5HT fiber growth	19384
The numbers of 5HT-labeled axons	19402
The numbers	19402
5HT-labeled axons	19417
all labeled axons crossing imaginary lines placed perpendicular to the rostralÐcaudal axis of the spinal cord at 500 µm rostral and 500 µm caudal to the edge of the graft as well as through the center of the graft	19463
all	19463
axons	19475
imaginary lines placed perpendicular to the rostralÐcaudal axis of the spinal cord at 500 µm rostral and 500 µm caudal to the edge of the graft as well as through the center of the graft	19490
imaginary lines	19490
the rostralÐcaudal axis of the spinal cord at 500 µm rostral and 500 µm caudal	19530
the rostralÐcaudal axis	19530
the spinal cord at 500 µm rostral and 500 µm caudal	19557
the spinal cord	19557
500 µm rostral and 500 µm caudal	19576
500 µm rostral	19576
500 µm caudal	19595
the edge of the graft	19612
the edge	19612
the graft	19624
the center of the graft	19653
the center	19653
the graft	19667
The graft	19678
double-labeling the sections with p75	19725
double-labeling the sections	19725
p75	19759
the transplant	19775
The number of fibers from the sections -LRB- 14-16 complete sections per spinal cord -RRB-	19791
The number	19791
fibers from the sections -LRB- 14-16 complete sections per spinal cord -RRB-	19805
fibers	19805
the sections -LRB- 14-16 complete sections per spinal cord -RRB-	19817
the sections	19817
14-16 complete sections per spinal cord	19831
14-16 complete sections	19831
spinal cord	19859
rat	19905
the number of fibers per section	19922
the number	19922
fibers per section	19936
fibers	19936
section	19947
the totals	19956
the number of sections examined	19988
the number	19988
sections examined	20002
sections	20002
Quantification of the intensity of GFAP immunoreactivity .	20021
Quantification	20021
the intensity	20039
GFAP immunoreactivity	20056
Digital images of GFAP immunoreactivity	20079
Digital images	20079
GFAP immunoreactivity	20097
2-mm-wide areas of the spinal cord rostral	20133
2-mm-wide areas	20133
the spinal cord rostral	20152
a perpendicular line	20193
the center of the injury / graft in four sections -LRB- two sections on either side of the central canal -RRB- from each animal -LRB- 5/group -RRB- at 12 weeks post-injury	20217
the center	20217
the injury / graft in four sections -LRB- two sections on either side of the central canal -RRB- from each animal -LRB- 5/group -RRB- at 12 weeks post-injury	20231
the injury	20231
graft in four sections -LRB- two sections on either side of the central canal -RRB- from each animal -LRB- 5/group -RRB- at 12 weeks	20243
graft	20243
four sections -LRB- two sections on either side of the central canal -RRB- from each animal -LRB- 5/group -RRB- at 12 weeks	20252
four sections -LRB- two sections on either side of the central canal -RRB-	20252
four sections	20252
two sections on either side of the central canal	20267
two sections	20267
either side of the central canal	20283
either side	20283
the central canal	20298
each animal -LRB- 5/group -RRB- at 12 weeks	20322
each animal -LRB- 5/group -RRB-	20322
each animal	20322
5/group	20335
12 weeks	20347
GFAP	20369
a marker for astrogliosis	20386
a marker	20386
astrogliosis	20399
These images	20413
intensity-measuring software -LRB- van der Lest et al. , University of Nijmegen , The Netherlands -RRB-	20451
intensity-measuring software	20451
van der Lest et al. , University of Nijmegen ,	20481
van der	20481
et al. , University of Nijmegen ,	20494
et al.	20494
University of Nijmegen	20502
University	20502
Nijmegen	20516
The Netherlands	20526
The software	20544
units , the total pixel intensity of the GFAP staining in each image	20603
units	20603
the total pixel intensity of the GFAP staining in each image	20610
the total pixel intensity	20610
the GFAP staining in each image	20639
the GFAP staining	20639
each image	20660
These values	20672
the four sections	20709
a mean	20735
GFAP intensity both rostral and caudal per animal	20742
GFAP intensity both rostral	20742
GFAP intensity	20742
rostral	20762
caudal per animal	20774
caudal	20774
animal	20785
Behavioral Testing BBB Open Field Locomotor Score .	20793
Behavioral Testing	20793
BBB Open Field Locomotor Score	20812
Hindlimb performance	20844
the open field locomotor test	20885
Basso	20928
et al. -LRB- 1995 , 1996 -RRB-	20934
et al.	20934
1995	20942
1996	20948
Two observers , unaware of the experimental procedures ,	20955
Two observers	20955
the experimental procedures	20981
the test	21020
a week	21034
8 weeks	21045
A BBB sub-score	21054
some animals	21096
a recovery pattern that did not follow the progression of the BBB score -LRB- Popovich et al. , 1999 -RRB-	21119
a recovery pattern	21119
the progression of the BBB score -LRB- Popovich et al. , 1999 -RRB-	21158
the progression	21158
the BBB score -LRB- Popovich et al. , 1999 -RRB-	21177
the BBB score	21177
Popovich	21192
et al. , 1999	21201
et al.	21201
1999	21209
Grid	21216
Test	21226
Deficits in descending motor control	21232
Deficits	21232
descending motor control	21244
8 weeks	21286
navigation	21307
a 1-m-long runway	21325
irregularly assigned gaps -LRB- 0.5 Ð5 cm -RRB- between round metal bars	21348
irregularly assigned gaps -LRB- 0.5 Ð5 cm -RRB-	21348
irregularly assigned gaps	21348
0.5 Ð5 cm	21375
round metal bars	21393
Metz	21438
et al. -LRB- 2000 -RRB-	21443
et al.	21443
2000	21451
this runway	21467
animals	21493
their limbs	21518
the bars	21533
baseline training and postoperative testing	21546
baseline training	21546
postoperative testing	21568
every animal	21591
the grid	21617
at least three times	21626
The number of footfalls -LRB- errors -RRB-	21648
The number	21648
footfalls -LRB- errors -RRB-	21662
footfalls	21662
errors	21673
each crossing	21696
each	21696
a mean error rate	21714
Footprint analysis .	21748
Footprint	21748
analysis	21758
Footprint analysis	21768
8 weeks using a protocol modified from de Medinaceli et al. -LRB- 1982 -RRB-	21804
8 weeks	21804
a protocol modified from de Medinaceli et al. -LRB- 1982 -RRB-	21818
a protocol	21818
de Medinaceli et al. -LRB- 1982 -RRB-	21843
de Medinaceli et al.	21843
The animalÕs	21872
paws	21890
footprints	21910
paper covering a narrow runway of 1 m in length and 7 cm in width	21934
paper	21934
a narrow runway of 1 m in length and 7 cm in width	21949
a narrow runway	21949
1 m in length and 7 cm in width	21968
1 m in length	21968
1 m	21968
length	21975
7 cm in width	21986
7 cm	21986
width	21994
This	22001
the direction of each step	22019
the direction	22019
each step	22036
standardized in line	22050
standardized	22050
line	22066
A series of at least eight sequential steps	22072
A series	22072
at least eight sequential steps	22084
the mean values	22138
each measurement of limb rotation , stride length and base of support	22158
each measurement	22158
limb rotation , stride length and base of support	22178
limb rotation	22178
stride length and base of support	22193
stride length and base	22193
support	22219
The base of support	22228
The base	22228
support	22240
the core-to-core distance of the central pads of the hind paws	22276
the core-to-core distance	22276
the central pads of the hind paws	22305
the central pads	22305
the hind paws	22325
The limb rotation	22340
the angle formed by the intersection of the line through the print of the third digit and the line through the central pad parallel to the walking direction	22373
the angle	22373
the intersection of the line	22393
the intersection	22393
the line	22413
the print of the third digit and the line	22430
the print	22430
the third digit and the line	22443
the third digit	22443
the line	22463
the central pad parallel	22480
the walking direction	22508
Stride length	22531
the central pads of two consecutive prints on each side	22566
the central pads	22566
two consecutive prints on each side	22586
two consecutive prints	22586
each side	22612
Statistical Analysis One-way ANOVA followed by FisherÕs	22623
Statistical Analysis One-way ANOVA	22623
FisherÕs	22670
least-significant difference -LRB- PLSD -RRB- test was used for comparing results of the tissue volume analysis , retrograde neuronal tracing and immunohistochemical detection of specific fiber types and staining intensities of GFAP	22689
least-significant difference -LRB- PLSD -RRB- test was used for comparing results of the tissue volume analysis , retrograde neuronal tracing	22689
least-significant difference	22689
PLSD	22719
test	22725
results of the tissue volume analysis , retrograde neuronal tracing	22753
results of the tissue volume analysis	22753
results	22753
the tissue volume analysis	22764
immunohistochemical detection of specific fiber types	22824
immunohistochemical detection	22824
specific fiber types	22857
staining intensities of GFAP	22882
staining intensities	22882
GFAP	22906
Multiple factor repeated ANOVA followed by the Tukey-Kramer test	22912
Multiple factor	22912
ANOVA followed by the Tukey-Kramer test	22937
ANOVA	22937
the Tukey-Kramer test	22955
comparison of weekly functional recovery patterns	22990
comparison	22990
weekly functional recovery patterns	23004
injury	23046
Differences	23054
statistically significant at p < 0.05 * , ,0.01 **	23086
statistically significant at p < 0.05 * , ,0.01	23086
statistically significant at p < 0.05 *	23086
statistically significant at p <	23086
p	23115
0.05 *	23119
,0.01	23126
,0.001 ***	23139
All errors	23150
standard deviations	23174
RESULTS	23196
1	23210
SUMMARY OF TISSUE VOLUME ANALYSIS OF A 9-MM CORD SEGMENT ENCOMPASSING THE INJURY TABLE 2 .	23213
SUMMARY OF TISSUE VOLUME ANALYSIS OF A 9-MM CORD SEGMENT	23213
SUMMARY	23213
TISSUE VOLUME ANALYSIS OF A 9-MM CORD SEGMENT	23224
TISSUE VOLUME ANALYSIS	23224
A 9-MM CORD SEGMENT	23250
THE INJURY TABLE 2	23283
SUMMARY OF THE BENEFICIAL AND ADVERSE EFFECTS OF EACH TREATMENT FIG. 1 .	23304
SUMMARY	23304
THE BENEFICIAL AND ADVERSE EFFECTS	23315
THE BENEFICIAL	23315
ADVERSE EFFECTS	23334
EACH TREATMENT FIG. 1	23353
EACH TREATMENT FIG.	23353
1	23374
MP/IL -10 , cell grafting or the combination	23377
MP/IL -10	23377
cell grafting	23387
the combination	23404
cavitation	23428
-LRB- A -RRB- Injured-only control .	23440
-LRB- A -RRB-	23440
Injured-only control	23444
-LRB- B -RRB- MP/IL -10 .	23466
-LRB- B -RRB-	23466
MP/IL -10	23470
-LRB- C -RRB- SC transplant .	23480
-LRB- C -RRB-	23480
SC transplant	23484
-LRB- D -RRB- MP/IL -10 and SC transplant .	23499
-LRB- D -RRB-	23499
MP/IL -10 and SC transplant	23503
MP/IL -10	23503
SC transplant	23516
-LRB- E -RRB- SC/OEG transplant .	23531
-LRB- E -RRB-	23531
SC/OEG transplant	23535
-LRB- F -RRB- MP/IL -10 and SC/OEG transplant .	23554
-LRB- F -RRB-	23554
MP/IL -10 and SC/OEG transplant	23558
MP/IL -10	23558
SC/OEG transplant	23571
The injury/transplant site	23590
the middle of the 9-mm-long segment of spinal cord	23623
the middle	23623
the 9-mm-long segment of spinal cord	23637
the 9-mm-long segment	23637
spinal cord	23662
Hematoxylin , eosin , and luxol fast blue-stained sagittal sections from within 200 µm lateral of the central canal .	23675
Hematoxylin	23675
eosin	23688
luxol fast blue-stained sagittal sections from within 200 µm lateral of the central canal	23699
luxol	23699
blue-stained sagittal sections from within 200 µm lateral of the central canal	23710
blue-stained sagittal sections	23710
200 µm lateral of the central canal	23753
200 µm lateral	23753
the central canal	23771
Bar	23790
1 mm	23796
FIG. 2 .	23803
FIG.	23803
2	23808
MP/IL -10 or cell transplantation	23811
MP/IL -10	23811
cell transplantation	23823
total cord volume and normal-appearing tissue volume	23854
cavitation	23921
-LRB- A -RRB- High magnification image of an SC-grafted spinal cord showing the border between normal-appearing tissue and damaged / grafted tissue -LRB- delineated by white arrows -RRB- .	23933
-LRB- A -RRB- High magnification	23933
A	23934
image of an SC-grafted spinal cord showing the border between normal-appearing tissue and damaged / grafted tissue -LRB- delineated by white arrows -RRB-	23956
image	23956
an SC-grafted spinal cord showing the border between normal-appearing tissue and damaged / grafted tissue -LRB- delineated by white arrows -RRB-	23965
an SC-grafted spinal cord	23965
the border between normal-appearing tissue	23999
the border	23999
normal-appearing tissue	24018
tissue	24063
white arrows	24085
The normal-appearing tissue	24100
viable neurons -LRB- yellow asterisks -RRB- , intact myelin and normal cellular density	24137
viable neurons -LRB- yellow asterisks -RRB-	24137
viable neurons	24137
yellow asterisks	24153
intact myelin and normal cellular density	24172
Bar	24215
50 µm	24221
-LRB- B -RRB- The total cord volume of a 9-mm region of the spinal cord encompassing the injury site at its center .	24228
-LRB- B -RRB- The total cord volume of a 9-mm region of the spinal cord	24228
-LRB- B -RRB-	24228
The total cord volume of a 9-mm region of the spinal cord	24232
The total cord volume	24232
a 9-mm region of the spinal cord	24257
a 9-mm region	24257
the spinal cord	24274
the injury site	24303
its center	24322
-LRB- C -RRB- The volume of cavitation within this 9-mm region expressed as a percentage of total cord volume .	24334
-LRB- C -RRB- The volume of cavitation within this 9-mm region	24334
The volume	24338
cavitation within this 9-mm region	24352
cavitation	24352
this 9-mm region	24370
a percentage of total cord volume	24400
a percentage	24400
total cord volume	24416
-LRB- D -RRB- The volume of normal-appearing tissue -LRB- gray and white matter combined -RRB- within this 9-mm region expressed as a percentage of normal , uninjured spinal cord volume .	24435
-LRB- D -RRB- The volume of normal-appearing tissue -LRB- gray and white matter combined -RRB-	24435
The volume	24439
normal-appearing tissue -LRB- gray and white matter combined -RRB-	24453
gray and white matter combined	24478
gray and white matter	24478
this 9-mm region expressed as a percentage of normal , uninjured spinal cord volume	24517
this 9-mm region	24517
a percentage of normal , uninjured spinal cord volume	24547
a percentage	24547
normal , uninjured spinal cord volume	24563
u , non-injured control ; , injured-only control ;	24601
u , non-injured control	24601
u	24601
non-injured control	24604
, injured-only control	24625
MP/IL -10 ; , SC transplant ; , SC transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant with MP/IL -10 ; ** p < 0.01 , *** p < 0.001 as compared to injury-only controls	24651
MP/IL -10 ; , SC transplant ; , SC transplant	24651
MP/IL -10	24651
SC transplant	24663
SC transplant	24680
MP/IL -10	24699
SC/OEG transplant ; j , SC/OEG transplant with MP/IL -10 ; ** p < 0.01 , *** p < 0.001 as compared to injury-only controls	24711
SC/OEG transplant	24711
j	24730
SC/OEG transplant with MP/IL -10 ; ** p < 0.01 , *** p < 0.001 as compared to injury-only controls	24733
SC/OEG transplant	24733
MP/IL -10 ; ** p < 0.01 , *** p < 0.001 as	24756
MP/IL -10	24756
p <	24768
p	24768
<	24770
0.01	24772
*** p	24778
0.001	24785
injury-only controls	24806
p <	24829
0.05	24833
cell only transplants , fp < 0.05 as compared to MP/IL -10 alone	24853
cell only transplants , fp <	24853
cell	24853
only transplants	24858
0.05	24881
-10	24906
FIG. 3 .	24918
FIG.	24918
3	24923
Anterogradely-traced supraspinal fibers	24926
SC/OEG grafts	24984
their numbers	25002
MP/IL -10	25037
The number of anterogradely	25047
The number	25047
anterogradely	25061
fibers/section 2500 µm rostral to	25082
fibers/section 2500 µm rostral	25082
2500 µm caudal	25129
the injury epicenter in the sensorimotor cortex -LRB- BDA -RRB- -LRB- A -RRB- , the reticular formation -LRB- DRh -RRB- -LRB- B -RRB- , and the vestibular nuclei -LRB- DFl -RRB- -LRB- C -RRB-	25147
the injury epicenter	25147
the sensorimotor cortex -LRB- BDA -RRB- -LRB- A -RRB- , the reticular formation -LRB- DRh -RRB- -LRB- B -RRB- , and the vestibular nuclei -LRB- DFl -RRB- -LRB- C -RRB-	25171
the sensorimotor cortex -LRB- BDA -RRB- -LRB- A -RRB-	25171
the sensorimotor cortex -LRB- BDA -RRB-	25171
the sensorimotor cortex	25171
BDA	25196
A	25202
the reticular formation -LRB- DRh -RRB- -LRB- B -RRB-	25206
the reticular formation -LRB- DRh -RRB-	25206
the reticular formation	25206
DRh	25231
B	25237
the vestibular nuclei -LRB- DFl -RRB- -LRB- C -RRB-	25245
the vestibular nuclei -LRB- DFl -RRB-	25245
the vestibular nuclei	25245
DFl	25268
C	25274
The graft	25278
p75 immunoreactivity	25306
SC transplant	25330
, SC transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant	25345
SC transplant	25347
MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG	25366
MP/IL -10 ; , SC/OEG transplant	25366
MP/IL -10	25366
SC/OEG transplant	25378
j , SC/OEG	25397
j	25397
SC/OEG	25400
MP/IL -10	25423
FIG. 4 .	25434
FIG.	25434
4	25439
Serotonergic fibers	25442
SC/OEG grafts	25486
-LRB- A -RRB- Diagram	25501
-LRB- A -RRB-	25501
Diagram	25505
the three perpendicular lines	25521
rostral	25551
the center	25566
caudal to the graft at which crossing 5HT1 fibers	25585
caudal	25585
the graft at which crossing 5HT1 fibers	25595
the graft	25595
5HT1 fibers	25623
-LRB- B -RRB- The mean numbers of serotonergic fibers present per section 500 µm rostral to and within the transplant site 11 weeks after transplantation .	25650
-LRB- B -RRB-	25650
The mean numbers of serotonergic fibers	25654
The mean numbers	25654
serotonergic fibers	25674
present per section 500 µm rostral to and within the transplant site	25694
present	25694
section 500 µm rostral	25706
the transplant site	25743
11 weeks after transplantation	25763
11 weeks	25763
transplantation	25778
The graft	25795
p75 immunoreactivity	25823
SC transplant	25847
, SC transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant	25862
SC transplant	25864
MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG	25883
MP/IL -10 ; , SC/OEG transplant	25883
MP/IL -10	25883
SC/OEG transplant	25895
j , SC/OEG	25914
j	25914
SC/OEG	25917
MP/IL -10	25940
FIG. 5 .	25951
FIG.	25951
5	25956
MP/IL -10 or SC/OEG grafting	25959
MP/IL -10	25959
SC/OEG grafting	25971
the number of reticulospinal , but not corticospinal or vestibulospinal , fibers	25997
the number	25997
reticulospinal , but not corticospinal or vestibulospinal , fibers	26011
the injury/transplant site	26086
The photographs	26114
Fast Blue-labeled neurons	26137
the reticular formation following labeling below the injury/transplant site after : -LRB- A -RRB- Injury only	26166
the reticular formation	26166
labeling below the injury/transplant site after : -LRB- A -RRB- Injury only	26200
labeling	26200
the injury/transplant site after : -LRB- A -RRB- Injury only	26215
the injury/transplant site	26215
-LRB- A -RRB- Injury only	26249
-LRB- A -RRB-	26249
Injury only	26253
-LRB- B -RRB- MP/IL -10 .	26266
-LRB- B -RRB-	26266
MP/IL -10	26270
-LRB- C -RRB- SC/OEG transplantation .	26280
-LRB- C -RRB-	26280
SC/OEG transplantation	26284
Bar 0 150 µm .	26308
Bar 0	26308
150 µm	26314
-LRB- DÐF -RRB- The number of retrogradely-labeled neurons with spared/regenerated fibers below the injury/transplant site in the sensorimotor cortex -LRB- D -RRB- , the reticular formation -LRB- E -RRB- , and the vestibular nuclei -LRB- F -RRB- .	26322
-LRB- DÐF -RRB-	26322
The number of retrogradely-labeled neurons with spared/regenerated fibers below the injury/transplant site in the sensorimotor cortex -LRB- D -RRB- , the reticular formation -LRB- E -RRB- , and the vestibular nuclei -LRB- F -RRB-	26328
The number	26328
retrogradely-labeled neurons with spared/regenerated fibers below the injury/transplant site in the sensorimotor cortex -LRB- D -RRB- , the reticular formation -LRB- E -RRB- , and the vestibular nuclei -LRB- F -RRB-	26342
retrogradely-labeled neurons	26342
spared/regenerated fibers below the injury/transplant site in the sensorimotor cortex -LRB- D -RRB- , the reticular formation -LRB- E -RRB- , and the vestibular nuclei -LRB- F -RRB-	26376
spared/regenerated fibers	26376
the injury/transplant site in the sensorimotor cortex -LRB- D -RRB- , the reticular formation -LRB- E -RRB- , and the vestibular nuclei -LRB- F -RRB-	26408
the injury/transplant site	26408
the sensorimotor cortex -LRB- D -RRB- , the reticular formation -LRB- E -RRB- , and the vestibular nuclei -LRB- F -RRB-	26438
the sensorimotor cortex -LRB- D -RRB-	26438
the sensorimotor cortex	26438
D	26463
the reticular formation -LRB- E -RRB-	26467
the reticular formation	26467
E	26492
the vestibular nuclei -LRB- F -RRB-	26500
the vestibular nuclei	26500
F	26523
, injured-only control ; , MP/IL -10 ; , SC transplant ; , SC transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant with MP/IL -10 ; p values : * p < 0.05 , ** p < 0.01 as compared to injury-only controls .	26527
, injured-only control ; , MP/IL	26527
, injured-only control	26527
MP/IL	26553
-10 ; , SC transplant ; , SC transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant with MP/IL -10 ; p values : * p < 0.05 , ** p < 0.01 as compared to injury-only controls	26558
-10	26558
SC transplant	26565
SC	26582
transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant with MP/IL -10 ; p values :	26585
transplant	26585
MP/IL -10	26601
SC/OEG transplant ; j , SC/OEG transplant with MP/IL -10 ; p values :	26613
SC/OEG transplant	26613
j	26632
SC/OEG transplant with MP/IL -10 ; p values :	26635
SC/OEG transplant	26635
MP/IL -10 ; p values :	26658
MP/IL -10	26658
p values	26668
p <	26679
p	26679
<	26681
0.05	26683
p < 0.01 as compared to injury-only controls	26691
p <	26691
p	26691
0.01	26695
injury-only controls	26715
FIG. 6 .	26738
FIG.	26738
6	26743
MP/IL -10	26746
gliosis	26763
injury	26777
SC/OEG grafts	26785
host cord gliosis than SC grafts	26826
host cord gliosis	26826
SC grafts	26849
-LRB- A -RRB- Diagram showing the rostral and caudal 2 mm long regions on either side of a perpendicular line at the center of the injury/graft that were photographed to measure GFAP intensity .	26860
-LRB- A -RRB- Diagram	26860
-LRB- A -RRB-	26860
Diagram	26864
the rostral and caudal 2 mm	26880
regions	26913
either side of a perpendicular line	26924
either side	26924
a perpendicular line	26939
the center of the injury/graft that were photographed to measure GFAP intensity	26963
the center	26963
the injury/graft that were photographed to measure GFAP intensity	26977
the injury/graft	26977
GFAP intensity	27028
-LRB- B -RRB- The intensity of GFAP immunoreactivity -LRB- arbitrary units -RRB- at 11 weeks post-transplantation .	27044
-LRB- B -RRB-	27044
The intensity of GFAP immunoreactivity -LRB- arbitrary units -RRB- at 11 weeks post-transplantation	27048
The intensity	27048
GFAP immunoreactivity -LRB- arbitrary units -RRB- at 11 weeks post-transplantation	27065
GFAP immunoreactivity -LRB- arbitrary units -RRB-	27065
GFAP immunoreactivity	27065
arbitrary units	27088
11 weeks	27108
, injured-only control ; , MP/IL -10 ; , SC transplant ; , SC transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant	27139
, injured-only control ; , MP/IL -10 ; , SC transplant ; , SC transplant	27139
, injured-only control ; , MP/IL -10	27139
, injured-only control	27139
MP/IL	27165
-10	27170
SC transplant	27177
SC transplant	27194
MP/IL -10	27213
SC/OEG transplant ; j , SC/OEG transplant	27225
SC/OEG transplant	27225
j	27244
SC/OEG transplant	27247
SC/OEG	27247
transplant	27254
MP/IL -10	27270
p <	27281
p	27281
<	27283
0.05	27285
p < 0.01 as compared to injury-only controls , # p < 0.05 as compared to cell only transplants	27293
p <	27293
p	27293
0.01	27297
injury-only controls , # p <	27317
injury-only controls	27317
# p <	27339
0.05 as compared to cell only transplants	27344
cell only	27364
FIG. 7 .	27388
FIG.	27388
7	27393
Combination of MP/IL -10 and SC/OEG transplantation	27396
Combination	27396
MP/IL -10 and SC/OEG transplantation	27411
MP/IL -10	27411
SC/OEG transplantation	27424
early and persistent gross behavioral improvement	27456
-LRB- A -RRB- Open-field locomotor ability	27507
-LRB- A -RRB-	27507
Open-field locomotor ability	27511
weekly using the BBB score at 1Ð8 weeks	27553
weekly	27553
the BBB score	27566
1Ð8 weeks	27583
-LRB- B -RRB- Weekly subscore analysis of the BBB score to assess the number of features above 14 on the BBB scale at 1Ð8 weeks after transplantation .	27615
-LRB- B -RRB- Weekly subscore analysis of the BBB score	27615
-LRB- B -RRB-	27615
Weekly subscore analysis of the BBB score	27619
Weekly subscore analysis	27619
the BBB score	27647
the number of features above 14	27671
the number	27671
features above 14	27685
features	27685
14	27700
the BBB scale	27706
1Ð8 weeks	27723
transplantation	27739
ÐsÐ , injured-only control ; ÐdÐ MP/IL -10 ; ÐuÐ , SC transplant ; ÐjÐ , SC transplant with MP/IL -10 ; ÐeÐ , SC/OEG transplant ; ÐrÐ , SC/OEG transplant with MP/IL -10 ; p values : * p < 0.05 , ** p < 0.01 as compared to injury-only controls .	27756
ÐsÐ , injured-only control ; ÐdÐ MP/IL -10 ; ÐuÐ , SC transplant ; ÐjÐ , SC transplant with MP/IL -10 ; ÐeÐ , SC/OEG transplant ; ÐrÐ , SC/OEG transplant with MP/IL -10 ; p values : * p <	27756
ÐsÐ , injured-only control	27756
ÐsÐ	27756
injured-only control	27761
ÐdÐ MP/IL -10	27783
ÐdÐ MP/IL	27783
-10	27792
ÐuÐ , SC transplant	27797
ÐuÐ	27797
SC transplant	27802
ÐjÐ , SC transplant with MP/IL -10	27817
ÐjÐ	27817
SC transplant with MP/IL -10	27822
SC transplant	27822
MP/IL -10	27841
ÐeÐ , SC/OEG transplant	27851
ÐeÐ	27851
SC/OEG transplant	27856
ÐrÐ , SC/OEG transplant with MP/IL -10	27875
ÐrÐ	27875
SC/OEG transplant with MP/IL -10	27880
SC/OEG transplant	27880
MP/IL -10	27903
p values : * p <	27913
p values	27913
p	27924
<	27926
0.05 , ** p <	27928
0.05	27928
p <	27936
p	27936
<	27938
0.01	27940
injury-only controls	27960
FIG. 8 .	27983
FIG.	27983
8	27988
MP/IL -10 administration or SC transplantation	27991
MP/IL -10 administration	27991
SC transplantation	28018
fine locomotor performance	28046
8 weeks	28076
their combination	28089
outcome	28129
-LRB- A -RRB- The angle of foot exo-rotation of the hind paws .	28138
-LRB- A -RRB-	28138
The angle of foot exo-rotation of the hind paws	28142
The angle	28142
foot exo-rotation of the hind paws	28155
foot exo-rotation	28155
the hind paws	28176
-LRB- B -RRB- The distance of the base of support between the hind paws .	28191
-LRB- B -RRB-	28191
The distance of the base of support between the hind paws	28195
The distance	28195
the base of support between the hind paws	28211
the base	28211
support between the hind paws	28223
support	28223
the hind paws	28239
-LRB- C -RRB- The stride length .	28254
-LRB- C -RRB-	28254
The stride length	28258
-LRB- D -RRB- The number of footfall errors of each hindlimb -LRB- maximum 20 -RRB- over 10 irregularly spaced bars on a gridwalk testing apparatus .	28277
-LRB- D -RRB- The number of footfall errors of each hindlimb -LRB- maximum 20 -RRB- over 10	28277
The number	28281
footfall errors of each hindlimb -LRB- maximum 20 -RRB- over 10	28295
footfall errors	28295
each hindlimb -LRB- maximum 20 -RRB- over 10	28314
each hindlimb -LRB- maximum 20 -RRB-	28314
each hindlimb	28314
maximum 20	28329
10	28346
bars on a gridwalk testing apparatus	28368
bars	28368
a gridwalk testing apparatus	28376
u , non-injured control ; , injured-only control ;	28406
u , non-injured control	28406
u	28406
non-injured control	28409
, injured-only control	28430
MP/IL -10 ; , SC transplant ; , SC transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant with MP/IL -10 ; p values : * p < 0.05 , ** p < 0.01 as compared to injury-only controls	28456
MP/IL -10 ; , SC transplant ; , SC	28456
MP/IL -10	28456
SC transplant	28468
SC	28485
transplant with MP/IL -10 ; , SC/OEG transplant ; j , SC/OEG transplant with MP/IL -10 ; p values :	28488
transplant	28488
MP/IL -10	28504
SC/OEG transplant ; j , SC/OEG transplant with MP/IL -10 ; p values :	28516
SC/OEG transplant	28516
j	28535
SC/OEG transplant with MP/IL -10 ; p values :	28538
SC/OEG transplant	28538
MP/IL -10 ; p values :	28561
MP/IL -10	28561
p values	28571
p <	28582
p	28582
<	28584
0.05	28586
p < 0.01 as compared to injury-only controls	28594
p <	28594
p	28594
0.01	28598
injury-only controls	28618
p <	28641
### p	28651
cell-only transplants	28679
Tissue Preservation Twelve weeks post-injury in SCI control spinal cords , the injury epicenter was dominated by one or more central cavities -LRB- Fig. 1A -RRB- surrounded by damaged tissue , devoid of viable neurons , containing fragmented myelin and permeated by numerous small cells , most likely infiltrating immune cells .	28703
Tissue Preservation Twelve weeks	28703
Tissue Preservation	28703
Twelve weeks	28723
SCI control spinal cords	28751
the injury epicenter	28777
one or more central cavities -LRB- Fig. 1A -RRB- surrounded by damaged tissue , devoid of viable neurons , containing fragmented myelin and permeated by numerous small cells , most likely infiltrating immune cells	28815
one or more central cavities -LRB- Fig. 1A -RRB-	28815
one or more central cavities	28815
Fig. 1A	28845
damaged tissue , devoid of viable neurons , containing fragmented myelin and permeated by numerous small cells , most likely infiltrating immune cells	28868
damaged tissue	28868
viable neurons , containing fragmented myelin and permeated by numerous small cells , most likely infiltrating immune cells	28894
viable neurons	28894
numerous small cells	28956
immune cells	29003
damaged tissue	29029
normal-appearing tissue	29071
numerous neurons , intact white matter and little or no cellular infiltration	29110
numerous neurons	29110
intact white matter	29128
little or no cellular infiltration	29152
The administration of MP/IL -10	29188
The administration	29188
MP/IL -10	29210
tissue cavitation -LRB- Fig. 1B -RRB-	29241
tissue cavitation	29241
Fig. 1B	29260
animals receiving either SC or SC/OEG grafts	29273
animals	29273
SC or SC/OEG grafts	29298
the grafts	29319
host spinal tissue	29351
the presence of only a few , small areas of cavitation at the interface regions in all transplanted animals -LRB- Fig. 1CÐF -RRB-	29376
the presence of only a few	29376
the presence	29376
only a few	29392
small areas of cavitation at the interface regions in all transplanted animals -LRB- Fig. 1CÐF -RRB-	29404
small areas	29404
cavitation at the interface regions in all transplanted animals -LRB- Fig. 1CÐF -RRB-	29419
cavitation	29419
the interface regions in all transplanted animals -LRB- Fig. 1CÐF -RRB-	29433
the interface regions	29433
all transplanted animals -LRB- Fig. 1CÐF -RRB-	29458
all transplanted animals	29458
Fig. 1CÐF	29484
the graft	29504
neurons	29530
high numbers of small cells -LRB- transplanted or immune cells -RRB-	29552
high numbers	29552
small cells -LRB- transplanted or immune cells -RRB-	29568
small cells	29568
transplanted or immune cells	29581
transplanted	29581
immune cells	29597
it	29612
damaged tissue without immunostaining -LRB- see below -RRB-	29647
damaged tissue without immunostaining	29647
damaged tissue	29647
immunostaining	29670
the graft	29707
normal-appearing spinal tissue which contained neurons	29742
normal-appearing spinal tissue	29742
neurons	29789
normal cellular density -LRB- Fig. 2A -RRB-	29829
normal cellular density	29829
Fig. 2A	29854
The volumes of the 9 mm segment of cord and cavitation after each intervention	29864
The volumes	29864
the 9 mm segment of cord and cavitation after each intervention	29879
the 9 mm segment	29879
cord and cavitation after each intervention	29899
cord and cavitation	29899
each intervention	29925
the uninjured rat	29962
the volume of the 9 mm segment of T8Ð10 spinal cord	29981
the volume	29981
the 9 mm segment of T8Ð10 spinal cord	29995
the 9 mm segment	29995
T8Ð10 spinal cord	30015
28.2 ± 1.2 mm3	30037
28.2 ±	30037
1.2 mm3	30044
injured groups	30056
a significant diminution of the total volume of the 9 mm cord segment	30072
a significant diminution	30072
the total volume of the 9 mm cord segment	30100
the total volume	30100
the 9 mm cord segment	30120
the control	30159
contused animals , the cord and cavity volumes	30172
contused animals	30172
the cord	30190
cavity volumes	30203
15.4 ± 1.5 and 6.0 ± 0.7 mm3	30223
15.4 ± 1.5 and 6.0	30223
15.4	30223
1.5 and 6.0	30230
0.7 mm3	30244
Table 1	30267
Fig. 2B	30276
The percentage of total cord volume , expressed in comparison to uninjured 9 mm blocks of spinal cord from the same region in a similarly-sized rat ,	30286
The percentage	30286
total cord volume	30304
comparison	30336
uninjured 9 mm blocks of spinal cord	30350
uninjured 9 mm blocks	30350
9	30360
spinal cord	30375
the same region in a similarly-sized rat	30392
the same region	30392
a similarly-sized rat	30411
54.7 ± 5.3 %	30438
54.7	30438
5.3 %	30445
the percentage of cavitation volume vs. the total cord volume	30454
the percentage	30454
cavitation volume vs. the total cord volume	30472
cavitation volume	30472
the total cord volume	30494
38.8 ± 2.7 % -LRB- Fig. 2C -RRB-	30520
38.8 ± 2.7 %	30520
38.8	30520
2.7 %	30527
Fig. 2C	30533
the animals that received MP/IL -10 or SC transplants	30546
the animals	30546
MP/IL -10 or SC transplants	30572
MP/IL -10	30572
SC transplants	30584
there	30600
a significant increase in the total cord volume -LRB- p < 0.01 -RRB- and a reduction in the volume of cavitation -LRB- p < 0.001 -RRB- -LRB- Table 1 , Fig. 2B , C -RRB-	30610
a significant increase in the total cord volume -LRB- p < 0.01 -RRB-	30610
a significant increase	30610
the total cord volume -LRB- p < 0.01 -RRB-	30636
the total cord volume	30636
p < 0.01	30659
p	30659
< 0.01	30661
<	30661
0.01	30663
a reduction in the volume of cavitation -LRB- p < 0.001 -RRB- -LRB- Table 1 , Fig. 2B , C -RRB-	30673
a reduction	30673
the volume of cavitation -LRB- p < 0.001 -RRB- -LRB- Table 1 , Fig. 2B , C -RRB-	30688
the volume	30688
cavitation -LRB- p < 0.001 -RRB- -LRB- Table 1 , Fig. 2B , C -RRB-	30702
cavitation -LRB- p < 0.001 -RRB-	30702
cavitation	30702
p < 0.001	30714
p	30714
< 0.001	30716
<	30716
0.001	30718
Table 1	30726
Fig. 2B	30735
C	30743
MP/IL -10 at 1 week before SC transplantation	30747
MP/IL -10	30747
1 week before SC transplantation	30759
1 week	30759
SC transplantation	30773
the volume of cavitation -LRB- p < 0.05 -RRB-	30808
the volume	30808
cavitation -LRB- p < 0.05 -RRB-	30822
cavitation	30822
p < 0.05	30834
p	30834
< 0.05	30836
<	30836
0.05	30838
SC/OEG grafting into the injury site at 1 week	30845
SC/OEG grafting	30845
the injury site at 1 week	30866
the injury site	30866
1 week	30885
the total cord volume over controls -LRB- p < 0.01 -RRB- and reduced cavitation -LRB- p < 0.001 -RRB- -LRB- Table 1 , Fig. 2B , C -RRB-	30902
the total cord volume	30902
controls -LRB- p < 0.01 -RRB- and reduced cavitation -LRB- p < 0.001 -RRB-	30929
controls -LRB- p < 0.01 -RRB-	30929
controls	30929
p < 0.01	30939
p	30939
< 0.01	30941
<	30941
0.01	30943
reduced cavitation -LRB- p < 0.001 -RRB-	30953
reduced cavitation	30953
p < 0.001	30973
p	30973
< 0.001	30975
<	30975
0.001	30977
Table 1	30985
Fig. 2B	30994
C	31002
MP/IL -10 with grafting further	31013
MP/IL -10	31013
cavitation -LRB- p < 0.05 -RRB-	31052
cavitation	31052
p < 0.05	31064
p	31064
< 0.05	31066
<	31066
0.05	31068
We	31075
these sections the amount of damaged tissue , i.e. , tissue that exhibited increased cellular density , myelin disruption and lack of neurons , as well as normal-appearing tissue , i.e. , tissue containing neurons , intact white matter and normal cellular density -LRB- Fig. 2A -RRB-	31095
these sections the amount of damaged tissue , i.e. , tissue that exhibited increased cellular density , myelin disruption and lack of neurons , as well as normal-appearing tissue , i.e. , tissue containing neurons	31095
the amount of damaged tissue , i.e. , tissue that exhibited increased cellular density , myelin disruption and lack of neurons , as well as normal-appearing tissue	31110
the amount	31110
damaged tissue , i.e. , tissue that exhibited increased cellular density , myelin disruption and lack of neurons , as well as normal-appearing tissue	31124
tissue	31132
tissue that exhibited increased cellular density , myelin disruption	31146
tissue	31146
increased cellular density , myelin disruption	31168
increased cellular density	31168
myelin disruption	31196
lack of neurons , as well as normal-appearing tissue	31218
lack	31218
neurons , as well as normal-appearing tissue	31226
neurons	31226
normal-appearing tissue	31246
tissue containing neurons	31277
tissue	31277
neurons	31295
intact white matter	31304
normal cellular density -LRB- Fig. 2A -RRB-	31328
normal cellular density	31328
Fig. 2A	31353
The damaged tissue volume	31363
a percentage of the total cord volume	31406
a percentage	31406
the total cord volume	31422
the same animal -LRB- Table 1 -RRB-	31449
the same animal	31449
Table 1	31466
The normal-appearing tissue volume	31476
a percentage of the average total cord volume of uninjured rat spinal cord	31532
a percentage	31532
the average total cord volume of uninjured rat spinal cord	31548
the average total cord volume	31548
uninjured rat spinal cord	31581
the transplanted animals damaged	31620
the transplanted animals	31620
tissue	31653
the graft	31692
damaged tissue volumes for these animals	31703
damaged tissue volumes	31703
these animals	31730
the graft	31771
the normal-appearing host spinal tissue	31809
it	31852
neurons or typical cellular density	31871
neurons	31871
typical cellular density	31882
the control	31911
contused animals	31924
the volumes of damaged and normal-appearing tissue were 1.5 6 1.0 mm3 -LRB- 10.0 ± 6.2 % -RRB- and 7.9 ± 1.1 mm3 -LRB- 28.0 ± 3.8 % -RRB- , respectively	31941
the volumes	31941
damaged and normal-appearing tissue were 1.5 6 1.0 mm3 -LRB- 10.0 ± 6.2 % -RRB- and 7.9 ± 1.1 mm3 -LRB- 28.0 ± 3.8 % -RRB- , respectively	31956
damaged and normal-appearing tissue	31956
1.5 6 1.0 mm3 -LRB- 10.0 ± 6.2 % -RRB- and 7.9 ± 1.1 mm3 -LRB- 28.0 ± 3.8 % -RRB-	31997
1.5 6 1.0 mm3 -LRB- 10.0 ± 6.2 % -RRB-	31997
1.5 6	31997
1.0 mm3 -LRB- 10.0 ± 6.2 % -RRB-	32003
1.0 mm3	32003
10.0 ± 6.2 %	32012
10.0	32012
6.2 %	32019
7.9 ± 1.1 mm3 -LRB- 28.0 ± 3.8 % -RRB-	32029
7.9 ±	32029
1.1 mm3 -LRB- 28.0 ± 3.8 % -RRB-	32035
1.1 mm3	32035
28.0 ± 3.8 %	32044
28.0	32044
3.8 %	32051
Table 1	32072
Fig. 2D	32081
the animals that received MP/IL -10	32094
the animals	32094
MP/IL -10	32120
there	32130
significant increases in the volumes of damaged tissue -LRB- p < 0.01 -RRB- and normal-appearing tissue -LRB- p < 0.01 -RRB- -LRB- Table 1 -RRB-	32141
significant increases	32141
the volumes of damaged tissue -LRB- p < 0.01 -RRB- and normal-appearing tissue -LRB- p < 0.01 -RRB- -LRB- Table 1 -RRB-	32166
the volumes	32166
damaged tissue -LRB- p < 0.01 -RRB- and normal-appearing tissue -LRB- p < 0.01 -RRB- -LRB- Table 1 -RRB-	32181
damaged tissue -LRB- p < 0.01 -RRB-	32181
damaged tissue	32181
p < 0.01	32197
p	32197
< 0.01	32199
<	32199
0.01	32201
normal-appearing tissue -LRB- p < 0.01 -RRB- -LRB- Table 1 -RRB-	32211
normal-appearing tissue -LRB- p < 0.01 -RRB-	32211
normal-appearing tissue	32211
p < 0.01	32236
p	32236
< 0.01	32238
<	32238
0.01	32240
Table 1	32247
Transplantation of SC or SC/OEG grafts	32257
Transplantation	32257
SC or SC/OEG grafts	32276
the amount of normal-appearing tissue -LRB- p < 0.01 -RRB- -LRB- Table 1 , Fig. 2D -RRB-	32306
the amount	32306
normal-appearing tissue -LRB- p < 0.01 -RRB- -LRB- Table 1 , Fig. 2D -RRB-	32320
normal-appearing tissue -LRB- p < 0.01 -RRB-	32320
normal-appearing tissue	32320
p < 0.01	32345
p	32345
< 0.01	32347
<	32347
0.01	32349
Table 1	32356
Fig. 2D	32365
Grafting of SCs or SCs/OEG subsequent to MP/IL10 administration	32375
Grafting	32375
SCs or SCs/OEG subsequent to MP/IL10 administration	32387
SCs or SCs/OEG	32387
MP/IL10 administration	32416
the volume of normal-appearing tissue	32471
the volume	32471
normal-appearing tissue	32485
MP/IL -10 alone -LRB- p < 0.05 -RRB-	32521
MP/IL -10 alone	32521
MP/IL -10	32521
p < 0.05	32537
p	32537
< 0.05	32539
<	32539
0.05	32541
Axons in the Graft and Beyond We used CNS nuclei-specific anterograde axon tracing to examine the presence of brainstem axons in grafts and beyond in each treatment group .	32548
Axons in the Graft and Beyond We used CNS	32548
Axons	32548
the Graft and Beyond	32557
the Graft	32557
Beyond	32571
We	32578
CNS	32586
nuclei-specific anterograde axon tracing to examine the presence of brainstem axons in grafts and beyond in each treatment group	32590
nuclei-specific anterograde axon	32590
the presence of brainstem axons	32642
the presence	32642
brainstem axons	32658
grafts	32677
each treatment group	32698
all groups	32723
corticospinal and vestibulospinal fibers	32735
grafts even with precedent MP/IL -10 -LRB- Fig. 3A , C -RRB-	32801
grafts even with precedent MP/IL -10	32801
grafts	32801
precedent MP/IL -10	32818
Fig. 3A , C	32838
Fig. 3A	32838
C	32846
many traced vestibulospinal fibers	32859
many	32859
vestibulospinal fibers	32871
preserved white matter around the injury/graft site	32911
preserved white matter	32911
the injury/graft site	32941
most corticospinal axons	32964
present rostral	32994
the grafted area	33013
axonal end bulbs , indicative of progressive degeneration -LRB- Tator , 1995 -RRB-	33044
axonal end bulbs	33044
progressive degeneration -LRB- Tator , 1995 -RRB-	33076
progressive degeneration	33076
Tator	33102
1995	33109
all grafted groups	33119
all	33119
groups	33131
some corticospinal axons	33139
only small sprouts	33173
the rostral graft/host interface	33199
SC only grafts	33236
SC only	33236
limited sprouting of reticulospinal fibers	33252
limited	33252
reticulospinal fibers	33273
most of the SC/OEG grafted animals -LRB- three of five -RRB-	33308
most	33308
the SC/OEG grafted animals -LRB- three of five -RRB-	33316
the SC/OEG	33316
animals -LRB- three of five -RRB-	33335
animals	33335
three of five	33344
three	33344
five	33353
a few labeled reticulospinal fibers -LRB- ,5 fibers/animal -RRB- , could be seen to reach the center of the graft and an occasional fiber	33369
a few	33369
reticulospinal fibers -LRB- ,5 fibers/animal -RRB- ,	33383
reticulospinal fibers	33383
,5 fibers/animal	33406
the center of the graft and an occasional fiber	33448
the center	33448
the graft and an occasional fiber	33462
the graft	33462
an occasional fiber	33476
the graft	33503
a short distance	33517
the caudal spinal cord	33539
both these grafted groups	33566
both these	33566
groups	33585
MP/IL -10	33593
the number of reticulospinal fibers present at the graft center -LRB- Fig. 3B -RRB-	33633
the number	33633
reticulospinal fibers present at the graft center -LRB- Fig. 3B -RRB-	33647
reticulospinal fibers present at the graft center	33647
reticulospinal fibers	33647
the graft center	33680
Fig. 3B	33698
Investigation of serotonergic fiber growth by 5HT immunohistochemistry	33708
Investigation	33708
serotonergic fiber growth by 5HT immunohistochemistry	33725
serotonergic fiber growth	33725
5HT immunohistochemistry	33754
these fibers	33791
both white and gray matter rostral	33820
the graft site	33858
Only SC/OEG grafts	33874
their growth	33901
the middle of the graft -LRB- 11.3 ± 6.3 fibers/section -RRB-	33919
the middle	33919
the graft -LRB- 11.3 ± 6.3 fibers/section -RRB-	33933
the graft	33933
11.3 ± 6.3 fibers/section	33944
11.3 ±	33944
6.3 fibers/section	33951
there	33972
no significant increase in fibers entering the grafts when MP/IL -10 was also administered -LRB- Fig. 4A , B -RRB-	33982
no significant increase	33982
fibers entering the grafts when MP/IL -10 was also administered -LRB- Fig. 4A , B -RRB-	34009
fibers	34009
the grafts	34025
MP/IL -10	34041
Fig. 4A , B	34073
Fig. 4A	34073
B	34081
The degree of fiber sparing/regeneration caudal to the injury/transplant site	34085
The degree	34085
fiber sparing/regeneration caudal to the injury/transplant site	34099
fiber sparing/regeneration caudal	34099
the injury/transplant site	34136
another set of animals following injection of the retrograde tracer , Fast Blue , caudal to the injury site	34184
another set	34184
animals following injection of the retrograde tracer , Fast Blue , caudal to the injury site	34199
animals	34199
injection of the retrograde tracer , Fast Blue , caudal to the injury site	34217
injection	34217
the retrograde tracer , Fast Blue , caudal to the injury site	34230
the retrograde tracer , Fast Blue ,	34230
the retrograde tracer	34230
Fast Blue	34253
the injury site	34274
neurons in the motor cortex	34299
neurons	34299
the motor cortex	34310
reticular formation and vestibular nucleus	34328
reticular formation	34328
vestibular nucleus	34352
Fig. 5DÐF	34388
spinal cord injured controls	34403
spinal cord	34403
controls	34423
the estimated total numbers of labeled neurons in the motor cortex , reticular formation and vestibular nuclei	34433
the estimated total numbers	34433
labeled neurons in the motor cortex , reticular formation and vestibular nuclei	34464
labeled neurons	34464
the motor cortex , reticular formation and vestibular nuclei	34483
the motor cortex	34483
reticular formation	34501
vestibular nuclei	34525
9.0 ± 3.8 , 3280 ± 560 , and 4370 ± 740 , respectively	34548
9.0 ± 3.8	34548
9.0 ±	34548
3.8	34554
3280 ± 560	34559
3280 ±	34559
560	34566
4370 ± 740 , respectively	34575
4370 ±	34575
740	34582
No significant change in the number of labeled neurons in the motor cortex and vestibular nuclei	34601
No significant change	34601
the number of labeled neurons in the motor cortex and vestibular nuclei	34626
the number	34626
labeled neurons in the motor cortex and vestibular nuclei	34640
neurons in the motor cortex	34648
neurons	34648
the motor cortex	34659
all treatment groups -LRB- Fig. 5D-F -RRB-	34714
all treatment groups	34714
Fig. 5D-F	34736
the other hand , MP/IL -10 or SC/OEG grafts	34751
the other hand	34751
MP/IL -10	34767
SC/OEG grafts	34779
regeneration of fibers from the reticular formation as seen by an increase in Fast Blue labeled neurons , 5220 ± 1290 -LRB- p < 0.05 -RRB- and 5790 ± 1340 -LRB- p < 0.01 -RRB- , respectively -LRB- Fig. 5E -RRB-	34812
regeneration	34812
fibers from the reticular formation as seen by an increase in Fast Blue labeled neurons , 5220 ± 1290 -LRB- p < 0.05 -RRB- and 5790 ± 1340 -LRB- p < 0.01 -RRB- , respectively -LRB- Fig. 5E -RRB-	34828
fibers	34828
the reticular formation as seen by an increase in Fast Blue labeled neurons , 5220 ± 1290 -LRB- p < 0.05 -RRB- and 5790 ± 1340 -LRB- p < 0.01 -RRB- , respectively -LRB- Fig. 5E -RRB-	34840
the reticular formation	34840
an increase in Fast Blue labeled neurons , 5220 ± 1290 -LRB- p < 0.05 -RRB- and 5790 ± 1340 -LRB- p < 0.01 -RRB-	34875
an increase	34875
Fast Blue labeled neurons , 5220 ± 1290 -LRB- p < 0.05 -RRB- and 5790 ± 1340 -LRB- p < 0.01 -RRB-	34890
Fast Blue	34890
neurons , 5220 ± 1290 -LRB- p < 0.05 -RRB- and 5790 ± 1340 -LRB- p < 0.01 -RRB-	34908
neurons , 5220	34908
neurons	34908
5220	34917
1290 -LRB- p < 0.05 -RRB- and 5790 ± 1340 -LRB- p < 0.01 -RRB-	34924
1290 -LRB- p < 0.05 -RRB-	34924
1290	34924
p < 0.05	34930
p	34930
< 0.05	34932
<	34932
0.05	34934
5790 ± 1340 -LRB- p < 0.01 -RRB-	34944
5790 ± 1340	34944
5790	34944
1340	34951
p < 0.01	34957
p	34957
< 0.01	34959
<	34959
0.01	34961
Fig. 5E	34982
The combination of MP/IL -10 with later SC/OEG grafting	34992
The combination	34992
MP/IL -10 with later SC/OEG grafting	35011
MP/IL -10	35011
later SC/OEG grafting	35025
reticulospinal fiber sparing/regeneration	35073
Modification of Host Cord	35116
Modification	35116
Host Cord	35132
Astroglial Reactivity We examined the degree of host spinal cord scarring rostral and caudal to the injury/transplantation site by assessing the intensity of GFAP immunoreactivity	35142
Astroglial Reactivity	35142
We	35164
the degree of host spinal cord scarring rostral and caudal to the injury/transplantation site	35176
the degree	35176
host spinal cord scarring rostral and caudal to the injury/transplantation site	35190
host spinal cord scarring rostral	35190
host	35190
spinal cord scarring rostral	35195
caudal to the injury/transplantation site	35228
caudal	35228
the injury/transplantation site	35238
the intensity of GFAP immunoreactivity	35283
the intensity	35283
GFAP immunoreactivity	35300
Fig. 6	35323
injured control animals	35335
the intensity of GFAP rostral and caudal to the injury epicenter , measured in arbitrary units ,	35360
the intensity	35360
GFAP rostral and caudal to the injury epicenter	35377
GFAP rostral and caudal	35377
the injury epicenter	35404
arbitrary units	35438
85.65 ± 14.32 and 110.27 ± 11.69	35459
85.65 ± 14.32 and 110.27	35459
85.65	35459
14.32 and 110.27	35467
11.69	35486
Fig. 6B	35507
GFAP immunoreactivity	35517
the injury site	35558
tissue bridges	35585
A significant reduction in GFAP intensity	35601
A significant reduction	35601
GFAP intensity	35628
the injury epicenter , 76.84 ± 12.09 -LRB- p < 0.05 -RRB-	35666
the injury epicenter	35666
76.84 ± 12.09 -LRB- p < 0.05 -RRB-	35688
76.84 ± 12.09	35688
76.84	35688
12.09	35696
p < 0.05	35703
p	35703
< 0.05	35705
<	35705
0.05	35707
rostral	35722
MP/IL -10 administration	35741
contrast	35775
grafting of SCs	35785
grafting	35785
SCs	35797
GFAP immunoreactivity both rostrally -LRB- 159.05 ± 18.01 ; p < 0.01 -RRB-	35825
GFAP immunoreactivity both rostrally	35825
GFAP immunoreactivity both	35825
GFAP immunoreactivity	35825
159.05 ± 18.01 ; p < 0.01	35863
159.05 ± 18.01 ; p <	35863
159.05 ± 18.01	35863
159.05	35863
18.01	35872
p <	35879
p	35879
<	35881
0.01	35883
192.34 ± 19.09 ; p < 0.01	35903
192.34 ± 19.09 ; p <	35903
192.34 ± 19.09	35903
192.34	35903
19.09	35912
p <	35919
p	35919
<	35921
0.01	35923
injury-only controls	35941
Animals with SC grafts	35963
Animals	35963
SC grafts	35976
an intense area of GFAP immunoreactive astrocytes surrounding the graft/injury site	35996
an intense area	35996
GFAP immunoreactive astrocytes surrounding the graft/injury site	36015
GFAP immunoreactive astrocytes	36015
the graft/injury site	36058
very few GFAP1 cells	36084
the grafts	36123
The intensity of GFAP immunoreactivity rostral and caudal to SC/OEG grafts	36135
The intensity	36135
GFAP immunoreactivity rostral and caudal to SC/OEG grafts	36152
GFAP immunoreactivity rostral	36152
caudal to SC/OEG grafts	36186
caudal	36186
SC/OEG grafts	36196
Fig. 6B	36239
the prior administration of MP/IL -10	36258
the prior administration	36258
MP/IL -10	36286
GFAP intensity	36303
17.5 % -LRB- p < 0.05 -RRB- in the caudal spinal cord	36321
17.5 % -LRB- p < 0.05 -RRB-	36321
17.5 %	36321
p < 0.05	36328
p	36328
< 0.05	36330
<	36330
0.05	36332
the caudal spinal cord	36341
SC grafting	36370
Functional Recovery All animals rapidly improved in hindlimb function in the first 2Ð3 weeks post-transplantation and then more	36383
Functional Recovery	36383
All animals	36403
hindlimb function	36435
the first 2Ð3 weeks post-transplantation and then more	36456
the first 2Ð3 weeks	36456
a plateau	36529
the next 5-6 weeks -LRB- Fig. 7A -RRB-	36544
the next 5-6 weeks	36544
Fig. 7A	36564
the group that received no treatment after contusion	36577
the group	36577
no treatment	36601
contusion	36620
the rats	36631
a stage at 8 weeks	36653
a stage	36653
8 weeks	36664
they	36678
occasional	36693
frequent weight-supported plantar steps	36707
little hindlimb-forelimb -LRB- HL-FL -RRB- coordination -LRB- BBB , 10.6 ± 1.1 -RRB-	36761
little hindlimb-forelimb -LRB- HL-FL -RRB- coordination	36761
little hindlimb-forelimb -LRB- HL-FL -RRB-	36761
little hindlimb-forelimb	36761
HL-FL	36787
BBB , 10.6 ± 1.1	36808
BBB , 10.6 ±	36808
BBB	36808
10.6 ±	36813
1.1	36820
injury only controls	36838
injury only	36838
a significant improvement in motor performance -LRB- p < 0.05 -RRB-	36860
a significant improvement in motor performance	36860
a significant improvement	36860
motor performance	36889
p < 0.05	36908
p	36908
< 0.05	36910
<	36910
0.05	36912
the combination of SC/OEG grafting and acute MP/IL -10	36937
the combination	36937
SC/OEG grafting and acute MP/IL -10	36956
SC/OEG grafting	36956
acute MP/IL -10	36976
These animals	36992
consistent plantar stepping with occasional to frequent coordination -LRB- BBB , 12.7 ± 0.4 -RRB-	37016
consistent plantar	37016
occasional to frequent coordination	37049
occasional	37049
frequent coordination	37063
BBB , 12.7 ± 0.4	37086
BBB , 12.7 ±	37086
BBB	37086
12.7 ±	37091
0.4	37098
The employment of a subscore for the BBB score	37104
The employment	37104
a subscore for the BBB score	37122
a subscore	37122
the BBB score	37137
us	37159
the presence of certain features	37173
the presence	37173
certain features	37189
score 14Ñe	37212
g. , foot placement , toe clearance , and tail position Ñthat	37223
g.	37223
foot placement	37227
toe clearance	37243
tail position Ñthat	37262
a different order	37300
the BBB scale -LRB- scored on a 0-13-point scale -RRB-	37326
the BBB scale	37326
a 0-13-point scale	37351
a BBB subscore of 3 ± 1.9 at 8 weeks -LRB- Fig. 7B -RRB-	37403
a BBB subscore	37403
3 ± 1.9 at 8 weeks -LRB- Fig. 7B -RRB-	37421
3 ± 1.9 at 8 weeks	37421
3 ±	37421
1.9 at 8 weeks	37425
Fig. 7B	37441
Animals	37451
SC/OEG	37472
prior MP/IL	37496
-10 administration , showed significantly higher BBB subscores , i.e. , exhibited more features -LRB- BBB score of .14 -RRB- from week 3 to 8 compared to the injured-only controls , with scores at endpoint being 7.3 ± 0.5 -LRB- p < 0.01 -RRB- and 7.2 ± 1.3 -LRB- p < 0.01 -RRB- , respectively	37507
-10 administration	37507
significantly higher BBB subscores	37534
more features -LRB- BBB score of .14 -RRB-	37586
more features	37586
BBB score of .14	37601
BBB score	37601
.14	37614
week 3 to 8	37624
the injured-only controls	37648
scores at endpoint being 7.3 ± 0.5 -LRB- p < 0.01 -RRB- and 7.2 ± 1.3 -LRB- p < 0.01 -RRB- , respectively	37680
scores at endpoint being 7.3 ± 0.5 -LRB- p < 0.01 -RRB- and 7.2 ± 1.3 -LRB- p < 0.01 -RRB-	37680
scores at endpoint being 7.3 ± 0.5 -LRB- p < 0.01 -RRB- and 7.2 ± 1.3	37680
scores	37680
endpoint being 7.3 ± 0.5 -LRB- p < 0.01 -RRB- and 7.2 ± 1.3	37690
endpoint being 7.3 ± 0.5 -LRB- p < 0.01 -RRB-	37690
endpoint	37690
7.3 ± 0.5	37705
7.3	37705
0.5	37711
p < 0.01	37716
p	37716
< 0.01	37718
<	37718
0.01	37720
7.2 ± 1.3	37730
7.2	37730
1.3	37736
p < 0.01	37741
p	37741
< 0.01	37743
<	37743
0.01	37745
No significant difference	37766
SC/OEG-only and SC/OEG 1 MP/IL -10 groups	37809
SC/OEG-only	37809
SC/OEG 1 MP/IL -10 groups	37825
SC/OEG 1 MP/IL	37825
-10 groups	37839
Footprint analysis of the hindlimbs	37851
Footprint analysis	37851
the hindlimbs	37873
8 weeks	37904
Analysis of uninjured animals	37913
Analysis	37913
uninjured animals	37925
a mean angle of rotation of the hindlimbs of 12.9 ± 0.9 ° -LRB- Fig. 8A -RRB-	37952
a mean angle	37952
rotation of the hindlimbs of 12.9 ± 0.9 ° -LRB- Fig. 8A -RRB-	37968
rotation	37968
the hindlimbs of 12.9 ± 0.9 ° -LRB- Fig. 8A -RRB-	37980
the hindlimbs	37980
12.9 ± 0.9 ° -LRB- Fig. 8A -RRB-	37997
12.9 ± 0.9 °	37997
12.9 ±	37997
0.9 °	38004
Fig. 8A	38010
injury	38026
this parameter	38033
a mean	38061
30.4	38071
± 2.3 °	38076
animals that received SCs	38087
animals	38087
SCs	38109
foot exo-rotation	38114
25.7 ± 1.7 ° -LRB- p < 0.05 -RRB-	38159
25.7 ± 1.7 °	38159
25.7	38159
1.7 °	38166
p < 0.05	38172
p	38172
< 0.05	38174
<	38174
0.05	38176
administration of MP/IL -10	38189
administration	38189
MP/IL -10	38207
SC transplantation	38223
this benefit -LRB- p < 0.001 -RRB-	38276
this benefit	38276
p < 0.001	38290
p	38290
< 0.001	38292
<	38292
0.001	38294
foot exo-rotation compared to injured-only controls , 36.6 ± 1.9 ° -LRB- p < 0.01 -RRB-	38333
foot exo-rotation	38333
injured-only controls , 36.6 ± 1.9 ° -LRB- p < 0.01 -RRB-	38363
injured-only controls	38363
36.6 ± 1.9 ° -LRB- p < 0.01 -RRB-	38386
36.6 ±	38386
1.9 ° -LRB- p < 0.01 -RRB-	38393
p < 0.01	38399
p	38399
< 0.01	38401
<	38401
0.01	38403
The base of support , determined as the distance between the left and right hind paw central pads ,	38410
The base	38410
support	38422
the distance between the left and right hind paw central pads	38445
the distance	38445
the left and right hind paw central pads	38466
the left and right hind paw	38466
central pads	38494
any treatment	38530
The combination of MP/IL - 10 with SC transplantation significantly worsened the base of support , i.e. , increased trunk instability -LSB- 5.0 ± 0.4 cm vs. 4.1 ± 0.6 cm -LRB- p < 0.05 -RRB- , injured-only con - trols -RSB- -LRB- Fig. 8B -RRB- .	38545
The combination of MP/IL	38545
The combination	38545
MP/IL	38564
10 with SC transplantation significantly worsened the base of support	38571
10	38571
SC transplantation significantly worsened the base of support	38579
SC transplantation	38579
the base of support	38621
the base	38621
support	38633
trunk instability	38658
5.0 ± 0.4 cm vs. 4.1 ± 0.6 cm -LRB- p < 0.05 -RRB- , injured-only con - trols -RSB- -LRB- Fig. 8B -RRB-	38677
5.0 ±	38677
4.1 ± 0.6 cm -LRB- p < 0.05 -RRB- , injured-only con - trols -RSB- -LRB- Fig. 8B -RRB-	38694
0.6 cm -LRB- p < 0.05 -RRB- , injured-only con	38700
0.6 cm -LRB- p < 0.05 -RRB-	38700
p < 0.05	38708
p	38708
< 0.05	38710
<	38710
0.05	38712
injured-only con	38719
trols -RSB- -LRB- Fig. 8B -RRB-	38737
trols	38737
-RSB- -LRB- Fig. 8B -RRB-	38742
-RSB-	38742
Fig. 8B	38745
Stride length	38755
injury -LRB- Fig. 8C -RRB-	38804
injury	38804
Fig. 8C	38812
The ability to cross a grid with randomly spaced bars was assessed by counting the number of footfall errors -LRB- missed bars -RRB-	38822
a grid with randomly spaced bars was assessed by counting the number of footfall errors -LRB- missed bars -RRB-	38843
a grid with randomly	38843
a grid	38843
bars	38871
the number of footfall errors	38901
the number	38901
footfall errors	38915
bars	38939
each hindlimb	38953
uninjured animals	38971
the mean error rate in hindlimb footfalls	38990
the mean error rate	38990
hindlimb footfalls	39013
0.7 ± 0.5	39036
0.7	39036
0.5	39042
8 weeks after injury	39050
8 weeks	39050
injury	39064
animals	39072
a mean error rate of 15.1 ± 1.5 -LRB- Fig. 8D -RRB-	39090
a mean error rate	39090
15.1 ± 1.5 -LRB- Fig. 8D -RRB-	39111
15.1 ± 1.5	39111
Fig. 8D	39123
the interventions	39136
only the acute administration of MP/IL -10 by itself	39155
only the acute administration	39155
MP/IL -10 by itself	39188
MP/IL -10	39188
itself	39200
the number of footfall errors	39229
the number	39229
footfall errors	39243
the gridwalk	39262
10.5 ± 1.9 -LRB- p < 0.05 -RRB-	39279
10.5 ± 1.9	39279
p < 0.05	39291
p	39291
< 0.05	39293
<	39293
0.05	39295
contrast	39305
prior administration of MP/IL -10	39315
prior administration	39315
MP/IL -10	39339
the performance of SC transplanted animals	39371
the performance	39371
SC transplanted animals	39390
the gridwalk compared to SC-only animals , 17.1 ± 1.0 versus 13.1 ± 2.5 -LRB- p < 0.05 -RRB-	39417
the gridwalk	39417
SC-only animals , 17.1 ± 1.0 versus 13.1 ± 2.5	39442
SC-only animals	39442
17.1 ± 1.0 versus 13.1 ± 2.5	39459
17.1 ± 1.0	39459
17.1	39459
1.0	39466
13.1 ± 2.5	39477
13.1	39477
2.5	39484
p < 0.05	39489
p	39489
< 0.05	39491
<	39491
0.05	39493
DISCUSSION Administration of either MP/IL -10 or SC or SC/OEG transplantation	39501
DISCUSSION Administration	39501
either MP/IL -10 or SC or SC/OEG transplantation	39530
MP/IL -10	39537
SC or SC/OEG transplantation	39549
moderate contusive SCI of rat thoracic spinal cord	39585
moderate contusive SCI	39585
rat thoracic spinal cord	39611
the volume of normal-appearing tissue 12 weeks post-injury	39661
the volume	39661
normal-appearing tissue 12 weeks post-injury	39675
normal-appearing tissue	39675
12 weeks	39699
The combination of either cell transplantation strategy	39721
The combination	39721
either cell transplantation strategy	39740
MP/IL -10	39782
further reduced cavitation volume compared to single strategies but combinations	39791
further reduced cavitation volume	39791
single strategies but combinations	39837
single strategies	39837
combinations	39859
normal-appearing tissue as MP/IL -10	39908
normal-appearing tissue	39908
MP/IL -10	39935
none of the individual treatment strategies	39959
none	39959
the individual treatment strategies	39967
a significant improvement	40015
gross locomotor performance	40044
the combination of MP/IL -10 with later SC/OEG transplants	40073
the combination	40073
MP/IL -10 with later SC/OEG transplants	40092
MP/IL -10	40092
later SC/OEG transplants	40106
the BBB score	40154
injury-only controls	40173
MP/IL	40199
-10 addition	40204
SC-only transplants	40226
behavioral outcome	40264
Some significant improvements in fine motor control	40284
Some significant improvements	40284
fine motor control	40317
individual treatments	40354
A summary of these findings	40377
A summary	40377
these findings	40390
Table 2	40421
the current study	40433
both the protective and cell transplantation strategies	40452
the protective	40457
cell transplantation strategies	40476
cavitation	40516
the volume of normal-appearing tissue	40541
the volume	40541
normal-appearing tissue	40555
injuryonly controls	40593
Our results	40614
earlier findings of a decrease in cavitation	40634
earlier findings	40634
a decrease in cavitation	40654
a decrease	40654
cavitation	40668
SCI with MP -LRB- Green et al. , 1980 ; Behrmann et al. , 1994 ; Chen et al. , 1996 ; Oudega et al. , 1999 -RRB- , IL-10 -LRB- Bethea et al. , 1999 -RRB- , MP and IL-10 -LRB- Takami et al. , 2002a -RRB- or SC/OEG transplants -LRB- Takami et al. , 2002b -RRB-	40685
SCI	40685
MP -LRB- Green et al. , 1980 ; Behrmann et al. , 1994 ; Chen et al. , 1996 ; Oudega et al. , 1999 -RRB- , IL-10 -LRB- Bethea et al. , 1999 -RRB- , MP and IL-10 -LRB- Takami et al. , 2002a -RRB- or SC/OEG transplants -LRB- Takami et al. , 2002b -RRB-	40694
MP -LRB- Green et al. , 1980 ; Behrmann et al. , 1994 ; Chen et al. , 1996 ; Oudega et al. , 1999 -RRB-	40694
MP	40694
Green et al. , 1980 ; Behrmann et al. , 1994 ; Chen et al. , 1996 ; Oudega et al. , 1999	40698
Green	40698
et al. , 1980 ; Behrmann et al. , 1994 ; Chen et al. , 1996 ; Oudega et al. , 1999	40704
et al. , 1980	40704
et al.	40704
1980	40712
Behrmann et al. , 1994	40718
Behrmann	40718
et al. , 1994	40727
et al.	40727
1994	40735
Chen et al. , 1996	40741
Chen	40741
et al. , 1996	40746
et al.	40746
1996	40754
Oudega et al. , 1999	40760
Oudega	40760
et al. , 1999	40767
et al.	40767
1999	40775
IL-10 -LRB- Bethea et al. , 1999 -RRB-	40782
IL-10	40782
Bethea	40789
et al. , 1999	40796
et al.	40796
1999	40804
MP and IL-10 -LRB- Takami et al. , 2002a -RRB-	40811
MP and IL-10	40811
Takami	40825
et al. , 2002a	40832
et al.	40832
2002a	40840
SC/OEG transplants -LRB- Takami et al. , 2002b -RRB-	40850
SC/OEG transplants	40850
Takami	40870
et al. , 2002b	40877
et al.	40877
2002b	40885
The degree of normal-appearing tissue preservation	40893
The degree	40893
normal-appearing tissue preservation	40907
treatment strategies	40975
animals receiving MP/IL -10	40997
animals	40997
MP/IL -10	41015
a significantly greater volume of normal-appearing tissue	41037
a significantly greater volume	41037
normal-appearing tissue	41071
those given cell grafts	41100
This	41125
the difference in the timing of the two strategies , 15 minutes versus 1 week , respectively , and the different tissue damaging processes	41155
the difference	41155
the timing of the two strategies , 15 minutes versus 1 week , respectively , and the different tissue damaging processes	41173
the timing of the two strategies	41173
the timing	41173
the two strategies	41187
15 minutes versus 1 week , respectively	41207
15 minutes	41207
1 week , respectively	41225
1 week	41225
the different tissue damaging processes	41251
the different tissue	41251
damaging processes	41272
they	41296
The acute protective regimen of MP/IL -10	41309
The acute protective regimen	41309
MP/IL -10	41341
the peak of secondary tissue damage	41374
the peak	41374
secondary tissue damage	41386
cell transplantation	41418
a time when considerable secondary tissue loss had already occurred	41452
a time	41452
considerable secondary tissue loss	41464
Both MP and IL-10	41521
anti-inflammatory actions	41544
the acute inflammatory response	41584
SCI	41622
MP	41627
oxygen	41645
radical-induced lipid peroxidation -LRB- Anderson et al. , 1985 ; Koc et al. , 1999 -RRB-	41652
radical-induced lipid peroxidation	41652
Anderson	41688
et al. , 1985 ; Koc et al. , 1999	41697
et al.	41697
1985 ; Koc et al.	41705
1985	41705
Koc et al.	41711
Koc	41711
et al.	41715
1999	41723
spinal cord blood flow -LRB- Young and Flamm , 1982 ; Hall et al. , 1984 -RRB-	41740
spinal cord blood flow	41740
Young and Flamm	41764
Young	41764
Flamm	41774
1982 ; Hall et al. , 1984	41781
1982	41781
Hall et al. , 1984	41787
Hall	41787
et al. , 1984	41792
et al.	41792
1984	41800
aerobic energy metabolism -LRB- Braughler and Hall , 1983 ; 1984 -RRB-	41817
aerobic energy metabolism	41817
Braughler and Hall , 1983 ; 1984	41844
Braughler and Hall	41844
1983 ; 1984	41864
intracellular Ca21 accumulation -LRB- Young and Flamm , 1982 -RRB- , actions that would be expected to protect tissue during the acute phase of the injury	41889
intracellular Ca21 accumulation -LRB- Young and Flamm , 1982 -RRB-	41889
intracellular Ca21 accumulation	41889
Young and Flamm , 1982	41922
Young	41922
Flamm , 1982	41932
Flamm	41932
1982	41939
actions that would be expected to protect tissue during the acute phase of the injury	41946
actions	41946
tissue	41988
the acute phase of the injury	42002
the acute phase	42002
the injury	42021
contrast	42036
tissue protection mediated by SC or OEG grafts	42046
tissue protection	42046
SC or OEG grafts	42076
a result of their secreted factors that may not only promote axonal regeneration but also provide trophic support to and thus permit survival of the injured host cells	42108
a result	42108
their secreted factors that may not only promote axonal regeneration but also provide trophic support to and thus permit survival of the injured host cells	42120
their	42120
factors that may not only promote axonal regeneration but also provide trophic support to and thus permit survival of the injured host cells	42135
factors	42135
axonal regeneration	42169
trophic support	42206
survival of the injured host cells	42241
survival	42241
the injured host cells	42253
SCs	42277
a variety of growth factors that have been demonstrated to support neuronal survival , including nerve growth factor -LRB- Bandtlow et al. , 1987 -RRB- , brainderived neurotrophic factor -LRB- Meyer et al. , 1992 -RRB- , ciliary neurotrophic factor -LRB- Friedman et al. , 1992 ; Rende et al. , 1992 -RRB- , and glial cell lineÐderived neurotrophic factor -LRB- Widenfalk et al. , 2001 -RRB-	42289
a variety	42289
growth factors that have been demonstrated to support neuronal survival , including nerve growth factor -LRB- Bandtlow et al. , 1987 -RRB- , brainderived neurotrophic factor -LRB- Meyer et al. , 1992 -RRB- , ciliary neurotrophic factor -LRB- Friedman et al. , 1992 ; Rende et al. , 1992 -RRB- , and glial cell lineÐderived neurotrophic factor -LRB- Widenfalk et al. , 2001 -RRB-	42302
growth factors	42302
neuronal survival	42356
nerve growth factor -LRB- Bandtlow et al. , 1987 -RRB- , brainderived neurotrophic factor -LRB- Meyer et al. , 1992 -RRB- , ciliary neurotrophic factor -LRB- Friedman et al. , 1992 ; Rende et al. , 1992 -RRB- , and glial cell lineÐderived neurotrophic factor	42385
nerve growth factor -LRB- Bandtlow et al. , 1987 -RRB- , brainderived neurotrophic factor -LRB- Meyer et al. , 1992 -RRB- , ciliary neurotrophic factor -LRB- Friedman et al. , 1992 ; Rende et al. , 1992 -RRB- , and glial cell	42385
nerve growth factor -LRB- Bandtlow et al. , 1987 -RRB-	42385
nerve growth factor	42385
Bandtlow	42406
et al. , 1987	42415
et al.	42415
1987	42423
brainderived neurotrophic factor -LRB- Meyer et al. , 1992 -RRB-	42430
brainderived neurotrophic factor	42430
Meyer	42464
et al. , 1992	42470
et al.	42470
1992	42478
ciliary neurotrophic factor -LRB- Friedman et al. , 1992 ; Rende et al. , 1992 -RRB-	42485
ciliary neurotrophic factor	42485
Friedman	42514
et al. , 1992 ; Rende et al. , 1992	42523
et al.	42523
1992 ; Rende et al.	42531
1992	42531
Rende et al.	42537
Rende	42537
et al.	42543
1992	42551
glial cell	42562
neurotrophic factor	42586
Widenfalk	42607
et al. , 2001	42617
et al.	42617
2001	42625
Many of these neurotrophic factors	42632
Many	42632
these neurotrophic factors	42640
OEG -LRB- Boruch et al. , 2001 ; Woodhall et al. , 2001 -RRB-	42688
OEG	42688
Boruch	42693
et al. , 2001 ; Woodhall et al. , 2001	42700
et al.	42700
2001 ; Woodhall et al.	42708
2001	42708
Woodhall et al.	42714
Woodhall	42714
et al.	42723
2001	42731
Grafting of cells	42738
Grafting	42738
cells	42750
stabilization of the injury site	42772
stabilization	42772
the injury site	42789
lost tissue volume	42816
secondary tissue damage	42850
mechanical aggravation of the cyst	42877
mechanical aggravation	42877
the cyst	42903
the later phase of the injury	42919
the later phase	42919
the injury	42938
It	42950
these different mechanisms	42967
a combination of an acute tissue sparing intervention and later cellular grafting	42999
a combination	42999
an acute tissue sparing intervention and later cellular grafting	43016
an acute tissue	43016
intervention and later cellular grafting	43040
intervention	43040
later cellular grafting	43057
tissue preservation over either treatment alone	43116
tissue preservation	43116
either treatment alone	43141
a significant , two-fold reduction in the volume of cavitation	43174
a significant , two-fold reduction	43174
the volume of cavitation	43211
the volume	43211
cavitation	43225
either combination over the individual strategies	43254
either combination	43254
the individual strategies	43278
cell grafting subsequent to MP/IL10	43305
cell grafting	43305
MP/IL10	43333
the volume of normal-appearing tissue	43363
the volume	43363
normal-appearing tissue	43377
MP/IL10 alone	43413
Reductions in the volume of normal-appearing tissue	43428
Reductions	43428
the volume of normal-appearing tissue	43442
the volume	43442
normal-appearing tissue	43456
a result of the invasive procedure of cell grafting which may have damaged previously protected tissue through the initiation of a second , albeit smaller , cascade of injury-associated processes	43501
a result	43501
the invasive procedure of cell grafting	43513
the invasive procedure	43513
cell grafting	43539
previously protected tissue	43576
the initiation of a second , albeit smaller , cascade of injury-associated processes	43612
the initiation	43612
a second , albeit smaller , cascade of injury-associated processes	43630
a second , albeit smaller , cascade	43630
injury-associated processes	43667
the current study	43721
the transplantation field in general	43745
the transplantation field	43745
general	43774
it	43783
the introduction of exogenous cells into the injured spinal cord	43809
the introduction	43809
exogenous cells into the injured spinal cord	43829
exogenous cells	43829
the injured spinal cord	43850
an inflammatory response	43887
This response to either the invasive surgical procedure or to the grafted cells , could in turn	43913
This response	43913
either the invasive surgical procedure	43930
the grafted cells , could in turn	43975
the grafted cells	43975
turn	44003
tissue damage	44019
secondary injury associated with the cell transplantation procedure	44055
secondary injury	44055
the cell transplantation procedure	44088
it	44124
the tissue protectants	44158
others -LRB- Chen et al. , 1996 ; Nash et al. , 2002 -RRB-	44219
others	44219
Chen	44227
et al. , 1996 ; Nash et al. , 2002	44232
et al.	44232
1996 ; Nash et al.	44240
1996	44240
Nash et al.	44246
Nash	44246
et al.	44251
2002	44259
We	44266
more specifically axonal sparing	44283
a retrograde tracer caudal	44331
the injury/transplant site	44361
neurons	44412
specific brain regions that possessed fibers beyond the injury/transplant site and thus were able to take up the tracer	44423
specific brain regions	44423
fibers	44461
the injury/transplant site	44475
the tracer	44532
the motor cortex and vestibular nuclei	44547
the motor cortex	44547
vestibular nuclei	44568
no change in the number of labeled neurons	44587
no change	44587
the number of labeled neurons	44600
the number	44600
labeled neurons	44614
all treatments	44646
injured-only controls	44673
Administration of MP/IL -10	44696
Administration	44696
MP/IL -10	44714
the number of retrogradely-labeled neurons	44757
the number	44757
retrogradely-labeled neurons	44771
the reticular formation -LRB- by 59 % -RRB-	44803
the reticular formation	44803
59 %	44831
SC/OEG transplantation -LRB- 86 % -RRB-	44844
SC/OEG transplantation	44844
86 %	44868
The reticular formation	44874
an important brainstem region involved in the initiation of stepping , inter-limb coordination and posturing during gait modifications in the cat -LRB- Whelan , 1996 ; Prentice and Drew , 2001 -RRB-	44919
an important brainstem region	44919
the initiation of stepping , inter-limb coordination and posturing during gait modifications in the cat -LRB- Whelan , 1996 ; Prentice and Drew , 2001 -RRB-	44961
the initiation	44961
, inter-limb coordination and posturing	44987
, inter-limb coordination	44987
posturing	45017
gait modifications in the cat -LRB- Whelan , 1996 ; Prentice and Drew , 2001 -RRB-	45034
gait modifications	45034
the cat -LRB- Whelan , 1996 ; Prentice and Drew , 2001 -RRB-	45056
the cat	45056
Whelan , 1996 ; Prentice and Drew , 2001	45065
Whelan	45065
1996 ; Prentice and Drew	45073
1996	45073
Prentice and Drew	45079
2001	45098
No additional increase in the numbers of labeled neurons	45105
No additional increase	45105
the numbers of labeled neurons	45131
the numbers	45131
labeled neurons	45146
the combination of MP/IL -10	45176
the combination	45176
MP/IL -10	45195
cell transplantation paradigm	45216
We	45247
MP/IL -10	45267
the environment of the injured spinal cord	45285
the environment	45285
the injured spinal cord	45304
the regenerative response of damaged axons to grow across SC or SC/OEG grafts	45339
the regenerative response	45339
damaged axons to grow across SC or SC/OEG grafts	45368
SC or SC/OEG grafts	45397
supraspinal fibers	45426
SC/OEG grafts	45453
very few	45468
SC grafts	45494
this response	45508
an earlier protective treatment with MP/IL -10	45539
an earlier protective treatment	45539
MP/IL -10	45576
It	45586
MP	45620
dieback of vestibulospinal axons -LRB- Oudega et al. , 1999 -RRB-	45634
dieback	45634
vestibulospinal axons -LRB- Oudega et al. , 1999 -RRB-	45645
vestibulospinal axons	45645
Oudega	45668
et al. , 1999	45675
et al.	45675
1999	45683
the distance of corticospinal tract regeneration	45699
the distance	45699
corticospinal tract regeneration	45715
a cervical lesion grafted with OEG -LRB- Nash et al. , 2002 -RRB-	45755
a cervical lesion	45755
OEG -LRB- Nash et al. , 2002 -RRB-	45786
OEG	45786
Nash	45791
et al. , 2002	45796
et al.	45796
2002	45804
axonal growth	45822
a SC cell bridge transplanted in the completely transected rat spinal cord -LRB- Chen et al. , 1996 -RRB-	45841
a SC cell bridge	45841
the completely transected rat spinal cord -LRB- Chen et al. , 1996 -RRB-	45874
the	45874
rat spinal cord -LRB- Chen et al. , 1996 -RRB-	45900
rat spinal cord	45900
Chen	45917
et al. , 1996	45922
et al.	45922
1996	45930
No direct effect of IL-10 on axon growth	45937
No direct effect	45937
IL-10 on axon growth	45957
IL-10	45957
axon growth	45966
The administration of MP/IL -10 in the current experiment	46005
The administration	46005
MP/IL -10 in the current experiment	46027
MP/IL -10	46027
the current experiment	46039
the amount of astrogliosis -LRB- GFAP immunoreactivity -RRB-	46084
the amount	46084
astrogliosis	46098
GFAP immunoreactivity	46112
caudal	46135
the injury and par	46145
the increase	46179
astrogliosis seen in response to SC-only grafting	46195
astrogliosis	46195
response	46216
SC-only grafting	46228
Astrogliosis and the subsequent production of axon growth inhibitory extracellular matrix molecules by reactive astrocytes , such as chondroitin sulfate proteoglycans -LRB- Canning et al. , 1996 -RRB- ,	46246
Astrogliosis and the subsequent production of axon growth inhibitory extracellular matrix molecules by reactive astrocytes	46246
Astrogliosis	46246
the subsequent production of axon growth inhibitory extracellular matrix molecules by reactive astrocytes	46263
the subsequent production	46263
axon growth inhibitory extracellular matrix molecules by reactive astrocytes	46292
axon growth inhibitory extracellular matrix molecules	46292
reactive astrocytes	46349
chondroitin sulfate proteoglycans -LRB- Canning et al. , 1996 -RRB-	46378
chondroitin sulfate proteoglycans	46378
Canning	46413
et al. , 1996	46421
et al.	46421
1996	46429
a significant impediment to regeneration	46440
a significant impediment	46440
regeneration	46468
SCI -LRB- Bradbury et al. , 2002 -RRB-	46487
SCI	46487
Bradbury	46492
et al. , 2002	46501
et al.	46501
2002	46509
None of the individual treatments	46516
None	46516
the individual treatments	46524
a significant improvement in gross locomotor ability in the openfield -LRB- BBB score -RRB-	46562
a significant improvement	46562
gross locomotor ability in the openfield -LRB- BBB score -RRB-	46591
gross locomotor ability	46591
the openfield -LRB- BBB score -RRB-	46618
the openfield	46618
BBB score	46633
injury-only controls	46656
the combination of MP/IL -10 with later SC/OEG grafting	46682
the combination	46682
MP/IL -10 with later SC/OEG grafting	46701
MP/IL -10	46701
later SC/OEG grafting	46715
a significant improvement in BBB score	46753
a significant improvement	46753
BBB score	46782
controls	46797
a reduction in normal-appearing tissue observed with this combination compared to MP/IL10 alone	46815
a reduction	46815
normal-appearing tissue observed with this combination compared to MP/IL10 alone	46830
normal-appearing tissue	46830
this combination	46868
MP/IL10 alone	46897
This	46912
the fact	46937
there	46951
no significant reduction in axon sparing between the two groups	46961
no significant reduction	46961
axon sparing between the two groups	46989
axon sparing	46989
the two groups	47010
retrograde tracing	47036
retrograde	47036
the reduction in normal tissue volume	47070
the reduction	47070
normal tissue volume	47087
gray matter	47129
little bearing on motor function	47159
little bearing	47159
motor function	47177
this spinal cord level	47195
The employment of a BBB subscore to examine the recovery of features at the upper end of the BBB scale	47219
The employment	47219
a BBB subscore to examine the recovery of features at the upper end of the BBB scale	47237
the recovery of features	47263
the recovery	47263
features	47279
the upper end of the BBB scale	47291
the upper end	47291
the BBB scale	47308
animals with SC/OEG grafts	47334
animals	47334
SC/OEG grafts	47347
significant improvement	47371
toe clearance	47398
correct tail position	47426
the other groups	47461
no additional benefit of MP/IL -10 administration	47496
no additional benefit	47496
MP/IL -10 administration	47521
Investigation of fine motor performance using footprint analysis and gridwalk testing	47562
Investigation	47562
fine motor performance using footprint analysis and gridwalk testing	47579
fine motor performance	47579
footprint analysis and gridwalk testing	47608
footprint analysis	47608
gridwalk testing	47631
a significant improvement , fewer footfall errors on a gridwalk ,	47661
a significant improvement	47661
fewer footfall errors on a gridwalk	47688
fewer footfall errors	47688
a gridwalk	47713
animals treated with MP/IL -10	47728
animals	47728
MP/IL -10	47749
The degree of behavioral recovery -LRB- as revealed by BBB scoring -RRB- with systemic administration of IL-10 -LRB- and MP -RRB-	47759
The degree of behavioral recovery -LRB- as revealed by BBB scoring -RRB-	47759
The degree of behavioral recovery	47759
The degree	47759
behavioral recovery	47773
BBB scoring	47809
systemic administration	47827
IL-10 -LRB- and MP -RRB-	47854
IL-10	47854
that	47906
Bethea and colleagues -LRB- 1999 -RRB-	47923
Bethea	47923
colleagues -LRB- 1999 -RRB-	47934
colleagues	47934
1999	47946
a significant increase in tissue sparing observed in both studies and the use of the same SCI model	47961
a significant increase	47961
tissue sparing observed in both studies and the use of the same SCI model	47987
tissue sparing	47987
both studies and the use	48014
studies	48019
the use	48031
the same SCI model	48042
A possible explanation for this disparity	48062
A possible explanation	48062
this disparity	48089
the present study	48115
we	48133
Fischer rats , a more inbred strain	48141
Fischer rats	48141
a more inbred strain	48155
the Sprague-Dawley rat , which was used in the other study -LRB- Bethea et al. , 1999 -RRB-	48181
the Sprague-Dawley rat	48181
the other study -LRB- Bethea et al. , 1999 -RRB-	48223
the other study	48223
Bethea	48240
et al. , 1999	48247
et al.	48247
1999	48255
they	48270
Fischer rats	48287
transplantation studies in our laboratory and others -LRB- Weidner et al. , 1999 ; Thomas et al. , 2000 ; Bamber et al. , 2001 -RRB-	48322
transplantation studies	48322
our laboratory and others -LRB- Weidner et al. , 1999 ; Thomas et al. , 2000 ; Bamber et al. , 2001 -RRB-	48349
our laboratory and others	48349
Weidner et al. , 1999 ; Thomas et al. , 2000 ; Bamber et al. , 2001	48376
Weidner	48376
et al. , 1999 ; Thomas et al. , 2000 ; Bamber et al. , 2001	48384
et al. , 1999	48384
et al.	48384
1999	48392
Thomas et al. , 2000	48398
Thomas	48398
et al. , 2000	48405
et al.	48405
2000	48413
Bamber et al. , 2001	48419
Bamber	48419
et al. , 2001	48426
et al.	48426
2001	48434
It	48441
certain inflammatory responses	48471
strain specific	48506
some strains	48531
Ôimmune privileged Õ whereas others are not -LRB- Popovich et al. , 1997 ; Sams et al. , 2000 -RRB-	48548
Ôimmune privileged Õ whereas others are not	48548
Ôimmune privileged Õ	48548
others	48577
Popovich	48593
et al. , 1997 ; Sams et al. , 2000	48602
et al.	48602
1997 ; Sams et al.	48610
1997	48610
Sams et al.	48616
Sams	48616
et al.	48621
2000	48629
Animals receiving SC grafts	48636
Animals	48636
SC grafts	48654
a significant reduction	48679
the degree of foot exo-rotation	48706
the degree	48706
foot exo-rotation	48720
injured-only controls	48750
The combination of MP/IL -10 with cell transplantation	48773
The combination	48773
MP/IL -10 with cell transplantation	48792
MP/IL -10	48792
cell transplantation	48806
gridwalk and footprint results over the individual strategies	48855
gridwalk and footprint	48855
the individual strategies	48891
fact	48921
the combination of MP/IL -10 with SC grafting actually	48927
the combination	48927
MP/IL -10 with SC grafting actually	48946
MP/IL -10	48946
SC grafting actually	48960
SC	48960
motor performance compared to SC - or MP/IL -10-only animals ; there was a significantly greater base of support -LRB- less trunk stability -RRB- , a wider angle of foot exo-rotation , and more numerous footfall errors on the gridwalk test	48990
motor performance compared to SC - or MP/IL -10-only animals ; there was a significantly greater base of support -LRB- less trunk stability -RRB-	48990
motor performance compared to SC - or MP/IL -10-only animals ; there was a significantly greater base of support	48990
motor performance	48990
MP/IL -10-only animals	49027
there	49050
a significantly greater base of support	49060
a significantly greater base	49060
support	49092
less trunk stability	49101
a wider angle	49124
foot exo-rotation	49141
more numerous footfall errors on the gridwalk test	49164
more numerous footfall errors	49164
the gridwalk test	49197
The results	49216
previous studies	49251
MP	49291
the growth of fibers	49307
the growth	49307
fibers	49321
SC transplants -LRB- Chen et al. , 1996 -RRB-	49333
SC transplants	49333
Chen	49349
et al. , 1996	49354
et al.	49354
1996	49362
combination with OEG grafts -LRB- Nash et al. , 2002 -RRB-	49376
combination	49376
OEG grafts -LRB- Nash et al. , 2002 -RRB-	49393
OEG grafts	49393
Nash	49405
et al. , 2002	49410
et al.	49410
2002	49418
regeneration and behavioral recovery	49437
regeneration	49437
behavioral recovery	49454
there	49484
several important differences between the present and aforementioned studies : -LRB- i -RRB- the co-administration of IL-10 with MP ; IL-10 is a suppressor cytokine that can inhibit the scavenging activity of both macrophages and SCs , actions that may be important for wound healing ; -LRB- ii -RRB- the timing of MP administration in relation to cell transplantation , simultaneously in the former study versus a 1 week separation in the present study and ; -LRB- iii -RRB- the SCI models	49494
several important differences between the present and aforementioned studies : -LRB- i -RRB- the co-administration of IL-10 with MP ; IL-10 is a suppressor cytokine that can inhibit the scavenging activity of both macrophages and SCs , actions that may be important for wound healing ; -LRB- ii -RRB- the timing of MP administration in relation to cell transplantation , simultaneously in the former study versus a 1 week separation in the present study and ;	49494
several important differences between the present and aforementioned studies	49494
several important differences	49494
the present and aforementioned studies	49532
-LRB- i -RRB- the co-administration of IL-10 with MP ; IL-10 is a suppressor cytokine that can inhibit the scavenging activity of both macrophages and SCs , actions that may be important for wound healing ; -LRB- ii -RRB- the timing of MP administration in relation to cell transplantation , simultaneously in the former study versus a 1 week separation in the present study and ;	49572
the co-administration	49576
IL-10 with MP ; IL-10 is a suppressor cytokine that can inhibit the scavenging activity of both macrophages and SCs , actions that may be important for wound healing ; -LRB- ii -RRB- the timing of MP administration in relation to cell transplantation , simultaneously in the former study versus a 1 week separation in the present study and ;	49601
IL-10	49601
MP ; IL-10 is a suppressor cytokine that can inhibit the scavenging activity of both macrophages and SCs , actions that may be important for wound healing ; -LRB- ii -RRB- the timing of MP administration in relation to cell transplantation , simultaneously in the former study versus a 1 week separation in the present study and ;	49612
MP	49612
IL-10	49616
a suppressor cytokine that can inhibit the scavenging activity of both macrophages and SCs , actions that may be important for wound healing ; -LRB- ii -RRB- the timing of MP administration in relation to cell transplantation , simultaneously in the former study versus a 1 week separation in the present study and	49625
a suppressor cytokine	49625
the scavenging activity of both macrophages and SCs , actions that may be important for wound healing	49664
the scavenging activity of both macrophages and SCs	49664
the scavenging activity	49664
both macrophages and SCs	49691
actions that may be important for wound healing	49717
actions	49717
wound healing	49751
ii	49767
the timing of MP administration	49771
the timing	49771
MP administration	49785
relation to cell transplantation	49806
relation	49806
cell transplantation	49818
the former study versus a 1 week separation in the present study and	49858
the former study	49858
a 1 week separation in the present study and	49882
the present study	49905
the SCI models	49934
transection compared to contusive injury	49950
transection	49950
contusive injury	49974
very different pathophysiological features	50003
conclusion	50050
it	50062
SCI either tissue sparing interventions	50085
SCI	50085
tissue sparing interventions	50096
tissue loss and the accompanying behavioral deficits , or cell transplantation strategies	50136
tissue loss and the accompanying behavioral deficits	50136
tissue loss	50136
the accompanying behavioral deficits	50152
cell transplantation strategies	50193
the injured spinal cord	50259
function	50294
important roles in recovery	50314
important roles	50314
recovery	50333
SCI	50347
We	50352
a protective regimen -LRB- MP/IL -10 -RRB- and cell transplantation -LRB- SC and SC/OEG grafts -RRB-	50378
a protective regimen -LRB- MP/IL -10 -RRB-	50378
a protective regimen	50378
MP/IL -10	50400
cell transplantation -LRB- SC and SC/OEG grafts -RRB-	50414
cell transplantation	50414
SC and SC/OEG grafts	50436
SC	50436
SC/OEG grafts	50443
we	50458
significant improvements	50473
behavioral recovery over injured-only controls	50501
behavioral recovery	50501
injured-only controls	50526
the individual treatments	50568
We	50601
cell grafting subsequent to a protective regimen	50619
cell grafting	50619
a protective regimen	50647
normal-appearing tissue volume compared to the protective regimen	50679
normal-appearing tissue volume	50679
the protective regimen	50722
a need	50761
either re-administration of the protective agents at the time of cell grafting or a less invasive transplantation procedure	50772
re-administration of the protective agents at the time of cell grafting	50779
re-administration	50779
the protective agents at the time of cell grafting	50800
the protective agents	50800
the time of cell grafting	50825
the time	50825
cell grafting	50837
a less invasive transplantation procedure	50854
we	50911
a combination of MP/IL -10 and SC grafts-only	50931
a combination	50931
MP/IL -10 and SC grafts-only	50948
MP/IL -10	50948
SC grafts-only	50961
behavioral restitution	51001
both the individual treatments and injured-only controls	51029
the individual treatments	51034
injured-only controls	51064
The current study	51087
the importance of understanding how administered protective agents will alter the milieu of the injured spinal cord for transplanted cells and if they may interfere with the function of these cells	51116
the importance	51116
administered protective agents	51152
the milieu of the injured spinal cord for transplanted cells	51194
the milieu	51194
the injured spinal cord for transplanted cells	51208
the injured spinal cord	51208
transplanted cells	51236
they	51262
the function of these cells	51286
the function	51286
these cells	51302
